[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 740
1. Tixier H, Fraisse J, Chauffert B, Mayer F, Causeret S, Loustalot C, Deville C, Bonnetain F, Sagot P, Douvier S, Cuisenier J: Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer. Arch Gynecol Obstet; 2010 Mar;281(3):505-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The secondary aim was to determine the morbidity of this surgery.
  • CONCLUSION: The main aim of surgery for ovarian peritoneal carcinomatosis is to obtain a complete resection.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847452.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


2. Bouslimani A, Bec N, Glueckmann M, Hirtz C, Larroque C: Matrix-assisted laser desorption/ionization imaging mass spectrometry of oxaliplatin derivatives in heated intraoperative chemotherapy (HIPEC)-like treated rat kidney. Rapid Commun Mass Spectrom; 2010 Feb;24(4):415-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxaliplatin [1,2-diaminocyclohexane (dach)-Pt complex] is a platinum anticancer drug which is mainly used in the treatment of advanced colorectal cancer, particularly in Heated Intraoperative Chemotherapy (HIPEC) for the treatment of colorectal peritoneal carcinomatosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 John Wiley & Sons, Ltd.
  • (PMID = 20082287.001).
  • [ISSN] 1097-0231
  • [Journal-full-title] Rapid communications in mass spectrometry : RCM
  • [ISO-abbreviation] Rapid Commun. Mass Spectrom.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


3. Cotte E, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O: Management of peritoneal carcinomatosis from colorectal cancer: current state of practice. Cancer J; 2009 May-Jun;15(3):243-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of peritoneal carcinomatosis from colorectal cancer: current state of practice.
  • Peritoneal carcinomatosis is a common manifestation of colorectal cancer and has traditionally been regarded as a terminal disease with a short median survival.
  • Further collaboration between peritoneal surface malignancy treatment centers may help to standardize indications and techniques for hyperthermic intraperitoneal chemotherapy and peritonectomy.
  • The development and validation of novel protocols and guidelines will allow surgeons and oncologists who discover colorectal carcinomatosis to treat these patients effectively.
  • [MeSH-major] Colorectal Neoplasms / therapy. Peritoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556911.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


Advertisement
4. Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL: Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol; 2009 Dec;135(12):1637-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.
  • BACKGROUND: Advanced and recurrent ovarian cancer results in extensive spread of tumor on the peritoneal surfaces of the abdomen and pelvis.
  • We collectively review studies in the literature that report the efficacy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer peritoneal carcinomatosis.
  • The quality of each study was independently assessed and classified according to the time point of HIPEC use in various setting of ovarian cancer from the consensus statement of the Peritoneal Surface Oncology Group.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / therapy. Hyperthermia, Induced / methods. Intraoperative Care / methods. Ovarian Neoplasms / therapy. Ovariectomy / methods. Peritoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):439-40 [19245944.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3019-27 [12926156.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • [Cites] J Surg Oncol. 2006 Sep 15;94(4):316-24 [16917864.001]
  • [Cites] Int J Hyperthermia. 2007 Aug;23(5):431-42 [17701534.001]
  • [Cites] Cancer Treat Rev. 2001 Dec;27(6):365-74 [11908929.001]
  • [Cites] World J Surg Oncol. 2009 Feb 09;7:14 [19203351.001]
  • [Cites] Cancer Treat Res. 1996;82:79-100 [8849945.001]
  • [Cites] J Obstet Gynaecol Res. 2006 Dec;32(6):580-7 [17100820.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:26-8 [18336395.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):671-5 [16621425.001]
  • [Cites] Zentralbl Gynakol. 2003 Oct;125(10):424-9 [14628225.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):315-25 [18473354.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9 [15823105.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):325-32 [15297169.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4699-707 [16966687.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:3-11 [15839952.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):193-200 [17466362.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Cancer Res. 1980 Feb;40(2):256-60 [6766084.001]
  • [Cites] World J Surg. 2007 Sep;31(9):1813-20 [17629740.001]
  • [Cites] J Natl Cancer Inst. 2009 Jun 3;101(11):775-7 [19470952.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1186-91 [19356887.001]
  • [Cites] J Anat. 1995 Jun;186 ( Pt 3):453-67 [7559120.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):484-92 [17054002.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):900-7 [19474692.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):465-72 [12884919.001]
  • [Cites] World J Surg. 2004 Oct;28(10):1040-5 [15573262.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):685-91 [17219441.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1094-9 [12853352.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):90-6 [17173957.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2068-75 [11066047.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):27-32 [16368440.001]
  • [Cites] Gynecol Oncol. 2009 Jul;114(1):137-9; author reply 139 [19368962.001]
  • [Cites] J Surg Oncol. 2008 Sep 15;98(4):283-90 [18726895.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1161-3 [11870155.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):35-41 [14764027.001]
  • [Cites] J Surg Oncol. 2005 May 1;90(2):51-6; discussion 56-8 [15844187.001]
  • [Cites] Gynecol Oncol. 2009 Jun;113(3):335-40 [19345401.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] World J Surg Oncol. 2004 Jun 28;2:21 [15222884.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1348-53 [17470449.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2049-62 [8918397.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):4011-9 [16921055.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1070-6 [16875720.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19701772.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 52
  •  go-up   go-down


5. ten Raa S, van Grevenstein HM, ten Kate M, Mangundap KM, Hofland LJ, Jeekel H, Sluiter W, van Eijck CH: The influence of reactive oxygen species on the adhesion of pancreatic carcinoma cells to the peritoneum. Cell Adh Migr; 2007 Apr-Jun;1(2):77-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of reactive oxygen species on the adhesion of pancreatic carcinoma cells to the peritoneum.
  • Postoperative peritoneal carcinomatosis is a significant clinical problem after "curative" resection of pancreatic carcinoma.
  • Preoperative surgical trauma activates a cascade of peritoneal defense mechanisms responsible for postoperative intra-abdominal tumor recurrence.
  • Therefore ROS can partly be responsible for the enhanced post-operative intra-abdominal tumor recurrence.
  • [MeSH-major] Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Peritoneum / metabolism. Peritoneum / pathology. Reactive Oxygen Species / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5625-9 [11059751.001]
  • [Cites] J Pathol. 2001 Apr;193(4):530-7 [11276014.001]
  • [Cites] J Surg Oncol. 2003 Jan;82(1):51-6 [12501168.001]
  • [Cites] Cell Commun Adhes. 2003 May-Jun;10(3):141-54 [14668061.001]
  • [Cites] Am Surg. 2004 Mar;70(3):208-13; discussion 213-4 [15055843.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34643-54 [15155719.001]
  • [Cites] Biol Chem. 2004 Aug;385(8):755-61 [15449712.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):943-50 [15386356.001]
  • [Cites] Surgery. 1983 Sep;94(3):407-11 [6310807.001]
  • [Cites] J Immunol Methods. 1987 Nov 5;103(2):253-9 [2822806.001]
  • [Cites] Cancer Detect Prev. 1988;12(1-6):421-9 [3263198.001]
  • [Cites] N Engl J Med. 1989 Feb 9;320(6):365-76 [2536474.001]
  • [Cites] World J Surg. 1991 Sep-Oct;15(5):609-16 [1949860.001]
  • [Cites] J Surg Res. 1992 Sep;53(3):245-50 [1326682.001]
  • [Cites] J Invest Surg. 1993 Jan-Feb;6(1):9-23 [8452827.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1372-6 [8292113.001]
  • [Cites] Br J Surg. 1994 Jan;81(1):7-19 [8313126.001]
  • [Cites] Surg Endosc. 1996 May;10(5):490-4 [8658324.001]
  • [Cites] J Surg Oncol. 1998 Feb;67(2):77-84 [9486777.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):242-8 [9488523.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):372-9 [9527060.001]
  • [Cites] Arch Surg. 1998 Apr;133(4):383-9 [9565118.001]
  • [Cites] Br J Surg. 1965 Jun;52:471-6 [14296780.001]
  • [Cites] J Surg Oncol. 2005 Nov 1;92(2):124-9 [16231370.001]
  • [Cites] Pancreas. 2006 May;32(4):396-402 [16670622.001]
  • (PMID = 19329881.001).
  • [ISSN] 1933-6926
  • [Journal-full-title] Cell adhesion & migration
  • [ISO-abbreviation] Cell Adh Migr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Reactive Oxygen Species; 1AVZ07U9S7 / Xanthine; EC 1.17.3.2 / Xanthine Oxidase
  • [Other-IDs] NLM/ PMC2633975
  •  go-up   go-down


6. Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, Gilly FN: Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg; 2007 Sep;31(9):1813-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: A prospective single center study of 81 patients with recurrent or chemo-resistant peritoneal carcinomatosis from ovarian cancer was performed.
  • Altogether, 54 patients presented with extensive carcinomatosis (malignant nodules of >5 mm).
  • Carcinomatosis extent and completeness of cytoreduction (p = 0.02 and p <0.001, respectively) were identified as independent prognostic factors.
  • This strategy may be most effective in patients with limited carcinomatosis or when cytoreductive surgery provides sufficient downstaging.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / surgery. Drug Resistance, Neoplasm. Hyperthermia, Induced. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2007 Sep;31(9):1821 [17623233.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1144-53 [16456817.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):694-8 [11821450.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3019-27 [12926156.001]
  • [Cites] Tumori. 2001 May-Jun;87(3):120-6 [11504363.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):144-53 [10618617.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Mar;26(3):210-5 [11981459.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):915-33, xi [11641098.001]
  • [Cites] Surg Clin North Am. 2001 Aug;81(4):871-83 [11551131.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] J Surg Oncol. 2000 Sep;75(1):24-30 [11025458.001]
  • [Cites] Cancer Res. 1963 Mar;23:372-80 [14023863.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):663-8 [11078613.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Obstet Fertil. 2004 May;32(5):391-7 [15177208.001]
  • [Cites] Cancer Res. 1980 Apr;40(4):1165-8 [7188883.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2489-97 [15590951.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1329-36 [12168946.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):504-12 [11733963.001]
  • [Cites] World J Surg. 2004 Oct;28(10):1040-5 [15573262.001]
  • [Cites] Natl Cancer Inst Monogr. 1975 Oct;42:101-4 [1234624.001]
  • [Cites] Hepatogastroenterology. 1994 Apr;41(2):124-9 [8056398.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):219-28 [15050953.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):767-75 [10071265.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Oct;86(2):185-8 [10509789.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):764-70 [14675312.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):344-9 [11104603.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1801-5 [1919630.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1026-32 [15770211.001]
  • [Cites] World J Surg Oncol. 2004 Jun 28;2:21 [15222884.001]
  • [Cites] Obstet Gynecol. 2002 Jun;99(6):1008-13 [12052591.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Gynecol Oncol. 1995 Apr;57(1):61-5 [7705701.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):273-80 [15491746.001]
  • (PMID = 17629740.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Cai ZY, Galettis P, Lu Y, Morris DL, Pourgholami MH: Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. Anticancer Res; 2007 Jan-Feb;27(1A):417-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was hypothesized that intraperitoneal (i.p.) administration of ABZ in peritoneal carcinomatosis (PC) could lead to long exposure of tumor cells to high concentration of the drug and possibly to reduced systemic toxicity.

  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352262.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; F4216019LN / Albendazole; J39B52TV34 / albendazole sulfoxide
  •  go-up   go-down


8. Raft J, Parisot M, Marchal F, Tala S, Desandes E, Lalot JM, Guillemin F, Longrois D, Meistelman C: [Impact of the hyperthermic intraperitoneal chemotherapy on the fluid-electrolytes changes and on the acid-base balance]. Ann Fr Anesth Reanim; 2010 Oct;29(10):676-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Retentissements hydroélectrolytiques et acidobasiques de la chimiohyperthermie intrapéritonéale.
  • BACKGROUND: Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an innovative treatment of the peritoneal carcinomatosis with potential iatrogenicity.
  • The abdominal cavity was filled with the peritoneal dialysis fluid with dextrose 5%: volume of 2L/m(2).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Hyperthermia, Induced / adverse effects. Peritoneal Neoplasms / drug therapy. Water-Electrolyte Imbalance / etiology
  • [MeSH-minor] Adult. Body Fluids. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Peritoneum. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Fluid and Electrolyte Balance.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20797835.001).
  • [ISSN] 1769-6623
  • [Journal-full-title] Annales françaises d'anesthèsie et de rèanimation
  • [ISO-abbreviation] Ann Fr Anesth Reanim
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Chua TC, Liauw W, Robertson G, Morris DL: Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol Oncol; 2009 Oct;115(1):166-8; author reply 168-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis.
  • [MeSH-major] Hyperthermia, Induced / methods. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2010 Apr;117(1):146-7 [20096922.001]
  • [CommentOn] Gynecol Oncol. 2009 Jul;114(1):26-31 [19395008.001]
  • [CommentOn] Gynecol Oncol. 2009 Jul;114(1):137-9; author reply 139 [19368962.001]
  • (PMID = 19604568.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


10. Seeber S, Strumberg D: [Metastases with CUP syndrome]. Urologe A; 2006 May;45(5):614-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the time point of first diagnosis of CUP syndrome, usually more than 80% of the patients present a disseminated situation.
  • In patients with small cell malignancies, peritoneal carcinomatosis (in women), poorly differentiated carcinomas involving external lymph nodes, mediastinum, or retroperitoneum, but without metastases to viscera or bone, objective long-term responses are possible with combination chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / drug therapy. Palliative Care / methods. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / secondary
  • [MeSH-minor] Clinical Trials as Topic. Humans. Neoplasm Recurrence, Local / prevention & control. Practice Guidelines as Topic. Practice Patterns, Physicians'. Quality of Life. Syndrome. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Jan 1;57(1):120-4 [3940611.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):47-58 [12667308.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):210-4 [2302061.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):205-11 [11856596.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1720-5 [7541451.001]
  • [Cites] Pathologe. 2002 May;23(3):183-97 [12089786.001]
  • [Cites] Ann Surg Oncol. 2001 Jun;8(5):425-31 [11407517.001]
  • [Cites] Arch Intern Med. 1988 Sep;148(9):2035-9 [3046543.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Anticancer Res. 1993 Sep-Oct;13(5A):1619-23 [8239543.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):206-28 [8503017.001]
  • [Cites] Cancer Res. 1989 Aug 1;49(15):4311-5 [2743318.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5092-4 [15107816.001]
  • [Cites] Onkologie. 2001 Feb;24(1):38-43 [11441279.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Bull Cancer. 2001 Jun;88(6):619-27 [11459709.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1160-6 [9506364.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] J Pathol. 2001 Sep;195(1):41-52 [11568890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):143-7 [10758316.001]
  • [Cites] Ann Oncol. 2001 Nov;12 (11):1605-9 [11822762.001]
  • [Cites] Ugeskr Laeger. 2001 Mar 5;163(10):1432-6 [11257752.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):273-8 [8503023.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2056-66 [9164218.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):147-52 [11884050.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):43-8 [12542974.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3611-3 [12552964.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1306-11 [12881397.001]
  • [Cites] Wien Klin Wochenschr. 1989 Jul 14;101(14):464-72 [2672606.001]
  • [Cites] Clin Radiol. 2002 Dec;57(12):1073-7 [12475531.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • (PMID = 16710679.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 40
  •  go-up   go-down


11. Glehen O, Cotte E, Lifante JC, Arvieux C, Moles N, Brigand C, Beaujard AC, François Y, Gilly FN: Peritoneal carcinomatosis in digestive cancers: cytoreductive surgery combined with intraperitoneal chemohyperthermia. The experience in Centre Hospitalier et Universitaire Lyon Sud (CHLS). Acta Chir Belg; 2006 May-Jun;106(3):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis in digestive cancers: cytoreductive surgery combined with intraperitoneal chemohyperthermia. The experience in Centre Hospitalier et Universitaire Lyon Sud (CHLS).
  • Up to 2005, 420 patients were involved in different phase II studies for peritoneal carcinomatosis (PC) from colorectal, gastric or ovarian origin, as well as for pseudomyxoma peritonei and peritoneal mesothelioma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910000.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Bouquet W, Ceelen W, Adriaens E, Almeida A, Quinten T, De Vos F, Pattyn P, Peeters M, Remon JP, Vervaet C: In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC. Ann Surg Oncol; 2010 Sep;17(9):2510-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Peritoneal carcinomatosis (PC) remains a dreaded clinical syndrome and a common evolution of gastrointestinal and ovarian cancers.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Carcinogens / pharmacology. Hyperthermia, Induced. Paclitaxel / pharmacology. Peritoneum / drug effects. beta-Cyclodextrins / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339948.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Carcinogens; 0 / beta-Cyclodextrins; JV039JZZ3A / betadex; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS: Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease &lt; 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med; 2007 Dec 12;5:66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.
  • BACKGROUND: Pharmacokinetic advantages of intraperitoneal (IP) rhIL-12, tumor response to IP delivery of other cytokines as well as its potential anti-angiogenic effect provided the rationale for further evaluation of IPrhIL-12 in patients with persistent ovarian or peritoneal carcinoma.
  • METHODS: A phase 2 multi-institutional trial (NCI Study #2251) of IP rIL-12 (300 nanogram/Kg weekly) was conducted in patients with ovarian carcinoma or primary peritoneal carcinoma.
  • Patients treated with primary therapy for ovarian cancer who had no extraabdominal/parenchymal disease or bulky peritoneal disease were eligible.
  • Peritoneal fluid cytokine measurements demonstrated a > or = 3 fold relative increase post-rhIL-12: IFN-gamma, 5/5 pts; TNF-alpha , 1/5; IL-10, 4/5; IL-8, 5/5; and VEGF, 3/5.
  • CONCLUSION: IP IL-12 can safely be administered at this dose and schedule to patients after first line chemotherapy for ovarian/peritoneal carcinoma.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1996 Feb;14(2):343-50 [8636742.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3399-407 [9363872.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1515-24 [16533776.001]
  • [Cites] J Immunol. 1999 Dec 1;163(11):6251-60 [10570318.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 [7538593.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Cancer Treat Rep. 1978 Jan;62(1):1-11 [626987.001]
  • [Cites] Cancer Res. 1985 Sep;45(9):4447-53 [4028027.001]
  • [Cites] Eur J Cancer. 1990 Mar;26(3):353-8 [2141493.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1618-29 [2213099.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3686-95 [12473577.001]
  • [Cites] J Immunother. 2003 May-Jun;26(3):270-6 [12806280.001]
  • (PMID = 18076766.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA091555; United States / NCI NIH HHS / CA / U01 CA062461; United States / NCI NIH HHS / CA / 5R21-CA091555; United States / NCI NIH HHS / CA / UO1 CA062461
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Recombinant Proteins; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC2248163
  •  go-up   go-down


14. Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC: Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol; 2007 Oct;14(10):2730-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The dominant recurrence pattern was peritoneal carcinomatosis within 5 years and distant metastasis after 5 years post gastrectomy.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Prognosis. Survival Rate. Survivors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17632757.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Hioki M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kinoshita T: Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg; 2010 Mar;34(3):555-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis.
  • BACKGROUND: The aim of this study was to review prognosis following gastrectomy for gastric cancer patients with synchronous peritoneal carcinomatosis and to identify predictive factors for improving survival after gastrectomy in this setting.
  • METHODS: Records of all patients who underwent gastrectomy for gastric cancer with peritoneal dissemination in our center between 1993 and 2004 were reviewed.
  • RESULTS: Data of 101 patients who underwent gastrectomy for gastric cancer with peritoneal dissemination were available.
  • Peritoneal dissemination was classified as P1, metastasis to the adjacent peritoneum in 34 patients; P2, a few scattered metastases to the adjacent peritoneum in 13 patients; and P3, numerous metastases in 54 patients.
  • Seven factors were significant for overall survival: peritoneal carcinomatosis, peritoneal lavage cytology, macroscopic type, resection margin, extent of lymph node dissection, curative potential of gastric resection, and chemotherapy, including perioperative and postrecurrent chemotherapy.
  • Univariate analysis of gastric cancer patients with P1 or P2 carcinomatosis revealed only tumor differentiation to be significant.
  • CONCLUSIONS: Gastric cancer patients with P1/P2 carcinomatosis and well/moderately differentiated tumors are likely to have an improved survival after gastrectomy.
  • We emphasize that patients with good performance status and P1/P2 carcinomatosis should be considered appropriate surgical candidates before embarking on palliative systemic chemotherapy alone.
  • [MeSH-major] Carcinoma / mortality. Gastrectomy / mortality. Peritoneal Neoplasms / mortality. Stomach Neoplasms / mortality
  • [MeSH-minor] Analysis of Variance. Female. Humans. Lymph Node Excision / methods. Male. Middle Aged. Neoplasm Invasiveness. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2010 Sep;34(9):2267-8 [20544347.001]
  • [Cites] World J Surg. 1989 Sep-Oct;13(5):617-21; discussion 621-2 [2479177.001]
  • [Cites] Int Semin Surg Oncol. 2005 Feb 08;2(1):3 [15701175.001]
  • [Cites] Gan No Rinsho. 1986 Aug;32(10):1203-9 [2431172.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] J Surg Oncol. 1998 Sep;69(1):41-4 [9762890.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1219-21 [11677934.001]
  • [Cites] Surg Today. 1994;24(1):40-3 [7519911.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):602-6 [16617004.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1438-43 [12390389.001]
  • [Cites] World J Surg. 2004 Apr;28(4):369-75 [15022025.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1712-5 [14571824.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Gastric Cancer. 2001;4(1):1-8 [11706621.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1530-5 [17051604.001]
  • [Cites] Hepatogastroenterology. 1998 Jul-Aug;45(22):1183-8 [9756030.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1853-8 [12820469.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):364-7 [2910444.001]
  • [Cites] Int J Clin Oncol. 2008 Jun;13(3):196-200 [18553227.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Gastric Cancer. 2009;12(1):37-42 [19390930.001]
  • [Cites] Oncology. 2000 Feb;58(2):96-107 [10705236.001]
  • (PMID = 20082194.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Royal RE, Pingpank JF Jr: Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum. Semin Oncol; 2008 Apr;35(2):183-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum.
  • Peritoneal carcinomatosis (the implantation of tumor cells throughout the peritoneal cavity) occurs in as many as 50% of patients with colorectal cancer and in up to 25% is the only site of recurrence.
  • There is increasing evidence that aggressive debulking of peritoneal only disease followed by intraperitoneal chemotherapy can have significant impact on the patient's quality and sometimes quantity of life.
  • This chapter will provide an overview of the biologic basis of pathogenesis and the treatment of peritoneal metastases from colorectal cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Peritoneal Neoplasms / secondary. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396204.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


17. Gómez Portilla A: [Peritoneal carcinomatosis. Ten years of applying the new combined triple therapy. Personal experience]. Cir Esp; 2007 Dec;82(6):346-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal carcinomatosis. Ten years of applying the new combined triple therapy. Personal experience].
  • [Transliterated title] Carcinomatosis peritoneal. Diez años aplicando la nueva triple terapia combinada. Experiencia personal.
  • INTRODUCTION: Peritoneal carcinomatosis is the main problem in treating patients with advanced cancer; in addition to the lack demonstrably effective treatment, once diagnosed, this condition leads inexorably and rapidly to death.
  • There is no response to traditional systemic treatments and the mean survival is less than 12 months after diagnosis.
  • The application of a new combined triple therapy consisting of cytoreductive surgery together with perioperative intraperitoneal chemotherapy and heated intraoperative intraperitoneal chemotherapy followed by early post-operative intra-abdominal chemotherapy is providing good results, even occasionally with curative intent, which suggests a new alternative treatment strategy.
  • Long-term survival was achieved among patients treated for persistent diffuse carcinomatosis secondary to pseudomyxoma, ovarian carcinomatosis, primary malignant peritoneal mesotheliomas, and colon carcinomatosis.
  • In our experience, we were able to achieve an initial control of the disease in 83% of our patients, medium-term survival (3 years) in 20% and long-term survival in 12.5% in four of the disease entities included in our protocol for the treatment of carcinomatosis.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053504.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


18. Bonastre J, Chevalier J, Elias D, Classe JM, Ferron G, Guilloit JM, Marchal F, Meeus P, De Pouvourville G: Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer. Value Health; 2008 May-Jun;11(3):347-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer.
  • OBJECTIVES: Our purpose was to assess the cost-effectiveness of intraperitoneal chemohyperthermia (IPCH) compared to palliative chemotherapy (STANDARD) against peritoneal carcinomatosis arising from colorectal cancer.
  • METHODS: We performed a retrospective study of 96 patients whose peritoneal carcinomatosis had been diagnosed between January 1998 and December 2003 and treated either with IPCH or with palliative chemotherapy in French comprehensive cancer centers.
  • CONCLUSION: The ICER of IPCH is acceptable given the severity and burden of peritoneal carcinomatosis for which there is no alternative curative treatment.
  • [MeSH-major] Antineoplastic Agents / economics. Colorectal Neoplasms / pathology. Hyperthermia, Induced / economics. Palliative Care / economics. Peritoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489663.001).
  • [ISSN] 1524-4733
  • [Journal-full-title] Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • [ISO-abbreviation] Value Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Saif MW, Siddiqui IA, Sohail MA: Management of ascites due to gastrointestinal malignancy. Ann Saudi Med; 2009 Sep-Oct;29(5):369-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ascites is the pathological accumulation of fluid within the abdominal cavity.
  • Symptoms include abdominal distension, nausea, vomiting, early satiety, dyspnea, lower extremity edema, weight gain and reduced mobility.
  • There are many potential causes of ascites in cancer patients, including peritoneal carcinomatosis, malignant obstruction of draining lymphatics, portal vein thrombosis, elevated portal venous pressure from cirrhosis, congestive heart failure, constrictive pericarditis, nephrotic syndrome and peritoneal infections.
  • Median survival after diagnosis of malignant ascites is in the range of 1 to 4 months; survival is apt to be longer for ovarian and breast cancers if systemic anti-cancer treatments are available.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Oct;31(7):626-34 [10604107.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1207-14 [9816289.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):445-54 [10675474.001]
  • [Cites] Palliat Med. 2000 Jan;14(1):62-4 [10717726.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2733-7 [11732940.001]
  • [Cites] Palliat Med. 2002 May;16(3):213-8 [12046997.001]
  • [Cites] Hepatology. 2003 Jul;38(1):258-66 [12830009.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1646-54 [15084697.001]
  • [Cites] Surgery. 1974 Feb;75(2):299-304 [4590763.001]
  • [Cites] Arch Intern Med. 1979 Feb;139(2):235 [434979.001]
  • [Cites] Am J Clin Oncol. 1982 Apr;5(2):167-72 [6178284.001]
  • [Cites] Br J Surg. 1982 Aug;69(8):441-2 [7049306.001]
  • [Cites] J Surg Oncol. 1982 Aug;20(4):238-42 [6180252.001]
  • [Cites] Br J Surg. 1983 Aug;70(8):478-81 [6871638.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Mar 10;288(6419):749-51 [6423061.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2226-30 [6207907.001]
  • [Cites] Cancer. 1985 May 1;55(9):1973-8 [3978577.001]
  • [Cites] Hepatology. 1985 May-Jun;5(3):403-7 [3888808.001]
  • [Cites] Cancer Treat Rev. 1985 Dec;12 Suppl B:23-32 [3833327.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):644-51 [3718029.001]
  • [Cites] Hepatology. 1988 Sep-Oct;8(5):1104-9 [3417231.001]
  • [Cites] Adv Intern Med. 1990;35:365-73 [2405598.001]
  • [Cites] Ann Intern Med. 1990 Jun 15;112(12):889-91 [2187389.001]
  • [Cites] Eur J Cancer. 1991;27(2):121-5 [1827272.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Mar-Apr;7(2):161-4 [1571498.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1302-6 [1397889.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):102-9 [1427388.001]
  • [Cites] Cancer. 1993 Mar 15;71(6):2027-30 [7680276.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):337-42 [8277955.001]
  • [Cites] Am J Hosp Pharm. 1994 May 1;51(9):1184-92 [8042637.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):378-81 [7531600.001]
  • [Cites] Hepatology. 1996 Jan;23(1):164-76 [8550036.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2201-6 [8572625.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):6-14 [8653366.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):237-9 [8654603.001]
  • [Cites] Medsurg Nurs. 1995 Dec;4(6):468-71 [8696395.001]
  • [Cites] N Z Med J. 1997 Feb 14;110(1037):33-5 [9066565.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1899-902 [9717817.001]
  • [Cites] J Pain Symptom Manage. 1998 Aug;16(2):96-101 [9737100.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):381-5 [9887235.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):300-8 [16240400.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):589-97 [16434188.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):709-13 [16739342.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):908-13 [17140897.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2348-57 [17505860.001]
  • [Cites] J Nippon Med Sch. 2007 Oct;74(5):355-8 [17965529.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Dec;22(12):2161-6 [18031375.001]
  • [Cites] QJM. 2008 Feb;101(2):71-85 [18184668.001]
  • [Cites] Palliat Med. 1999 Sep;13(5):429-30 [10659116.001]
  • (PMID = 19700895.001).
  • [ISSN] 0975-4466
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC3290049
  •  go-up   go-down


20. Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, Stoeltzing O: Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer; 2010;10:668
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The impact of ATF3 down-regulation on cancer growth and metastasis were investigated in a subcutaneous tumor model, a model of hepatic tumor growth and in a model of peritoneal carcinomatosis.
  • Moreover, in xenogenic mouse models, ATF3 knock-down promoted subcutaneous tumor growth and hepatic metastasis, as well as peritoneal carcinomatosis.
  • [MeSH-major] Activating Transcription Factor 3 / metabolism. Antineoplastic Agents / pharmacology. Benzoquinones / pharmacology. Colonic Neoplasms / drug therapy. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / pharmacology. Liver Neoplasms / prevention & control. Peritoneal Neoplasms / prevention & control
  • [MeSH-minor] Animals. Cell Movement / drug effects. HCT116 Cells. Humans. Male. Mice. Mice, Nude. Neoplasm Invasiveness. RNA Interference. Time Factors. Transfection. Tumor Burden / drug effects. Up-Regulation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2007 Nov;6(11):2868-78 [18025273.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6459-68 [17975158.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):250-62 [18772114.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):370-4 [18644253.001]
  • [Cites] Cell Cycle. 2009 Feb 15;8(4):518-26 [19197160.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2118-27 [17952119.001]
  • [Cites] Jpn J Cancer Res. 2000 Aug;91(8):833-6 [10965025.001]
  • [Cites] Pathobiology. 2000;68(4-5):227-31 [11279351.001]
  • [Cites] J Cell Physiol. 2001 Sep;188(3):352-8 [11473362.001]
  • [Cites] Oncol Res. 2001;12(8):343-6 [11589305.001]
  • [Cites] J Cell Sci. 2002 Jul 15;115(Pt 14):2809-16 [12082142.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1182-7 [12402160.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):213-7 [12676580.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3370-7 [12810673.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1001-11 [12937141.001]
  • [Cites] Curr Opin Oncol. 2003 Nov;15(6):419-24 [14624223.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5721-32 [15199129.001]
  • [Cites] J Mol Med (Berl). 2004 Aug;82(8):488-99 [15168026.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):1021-30 [15299085.001]
  • [Cites] Ann Surg. 2005 May;241(5):748-56; discussion 756-8 [15849510.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):693-703 [15897233.001]
  • [Cites] J Biol Chem. 2006 Jan 20;281(3):1620-9 [16291753.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10473-81 [16469745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7625-30 [16684877.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10750-9 [17108111.001]
  • [Cites] Biochem J. 2007 Jan 15;401(2):559-67 [17014422.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11983-90 [17178897.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):284-9 [16847457.001]
  • [Cites] Mol Carcinog. 2007 Jun;46(6):476-87 [17295236.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1232-49 [18644986.001]
  • (PMID = 21129190.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATF3 protein, human; 0 / Activating Transcription Factor 3; 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  • [Other-IDs] NLM/ PMC3003660
  •  go-up   go-down


21. Santarpia L, Alfonsi L, Pasanisi F, De Caprio C, Scalfi L, Contaldo F: Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition. Nutrition; 2006 Apr;22(4):355-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition.
  • OBJECTIVE: We worked to identify predictors of survival in patients with carcinomatosis on home parenteral nutrition (HPN).
  • METHODS: Survival rate was evaluated in 152 terminal patients (45 men and 107 women) with peritoneal carcinosis on HPN.
  • In this study, traditional predictors (KPS, albumin, pain, and vomiting) and CHE level appeared to be a useful survival predictor index in incurable patients with peritoneal carcinosis on HPN.
  • [MeSH-major] Carcinoma / mortality. Cholinesterases / metabolism. Karnofsky Performance Status. Parenteral Nutrition, Home. Peritoneal Neoplasms / mortality

  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413750.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Serum Albumin; 97C5T2UQ7J / Cholesterol; EC 3.1.1.8 / Cholinesterases
  •  go-up   go-down


22. Hibi T, Ojima H, Sakamoto Y, Kosuge T, Shimada K, Sano T, Sakamoto M, Kitajima M, Yamasaki S: A solid pseudopapillary tumor arising from the greater omentum followed by multiple metastases with increasing malignant potential. J Gastroenterol; 2006 Mar;41(3):276-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A solid pseudopapillary tumor arising from the greater omentum followed by multiple metastases with increasing malignant potential.
  • Solid pseudopapillary tumor is a rare, indolent neoplasm almost exclusively seen in the pancreas.
  • We describe an unusual case of solid pseudopapillary tumor arising in the greater omentum of a 45-year-old man with subsequent multiple liver metastases and peritoneal dissemination.
  • We also performed quantitative evaluation of Ki-67 immunoreactivity and mitotic figures, which indicated malignant transformation of this extremely rare tumor.
  • This is the first detailed report of solid pseudopapillary tumor arising outside the pancreas complicated by repetitive liver metastases and peritoneal carcinomatosis, suggesting the existence of a more lethal subgroup of tumors.
  • [MeSH-major] Carcinoma, Papillary / secondary. Omentum / pathology. Pancreatic Neoplasms / secondary. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Fatal Outcome. Humans. Immunohistochemistry. Ki-67 Antigen / blood. Laparotomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Mesentery / pathology. Mesentery / surgery. Middle Aged. alpha 1-Antitrypsin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1990 Sep;108(3):475-80 [2396191.001]
  • [Cites] J Pediatr Surg. 1988 Feb;23(2):116-21 [3278085.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2740-6 [2340471.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1368-71 [11570919.001]
  • [Cites] World J Surg. 1999 Oct;23(10):1045-50 [10512945.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):283-91 [2295051.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] Am J Gastroenterol. 1993 Sep;88(9):1436-9 [8362844.001]
  • [Cites] J Pediatr Surg. 1995 May;30(5):724-6 [7623239.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):82-92 [8416730.001]
  • [Cites] Am J Clin Pathol. 1992 Nov;98(5):478-88 [1283055.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):512-9 [15767807.001]
  • [Cites] Cancer. 1985 Dec 15;56(12 ):2783-5 [4052952.001]
  • [Cites] Pediatr Radiol. 2003 Apr;33(4):269-71 [12709760.001]
  • [Cites] Lancet Oncol. 2005 Mar;6(3):185-6 [15737835.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Pancreatology. 2005;5(2-3):289-94 [15855828.001]
  • [Cites] Surgery. 2005 Jun;137(6):591-6 [15933625.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(2):179-83 [1705067.001]
  • [Cites] Am J Gastroenterol. 1990 May;85(5):597-601 [2337064.001]
  • (PMID = 16699862.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / SERPINA1 protein, human; 0 / alpha 1-Antitrypsin
  •  go-up   go-down


23. Catarino RM, Lopes JD, Forones NM, Parise ER: Laminin concentration in ascites of patients with hepatic cirrhosis and peritoneal carcinomatosis. Braz J Med Biol Res; 2005 Feb;38(2):271-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laminin concentration in ascites of patients with hepatic cirrhosis and peritoneal carcinomatosis.
  • We compared the concentration of laminin in serum and in ascitic fluid from patients with hepatic cirrhosis and peritoneal carcinomatosis and assessed the diagnostic value of serum laminin levels in differentiating neoplastic from benign ascites.
  • Laminin concentrations were determined by ELISA with antibodies against laminin extracted from the human placenta, in patients with ascites due to peritoneal carcinomatosis (N = 20) and hepatic cirrhosis (N = 33).
  • The receiver operating characteristic curve was used to determine the sensitivity and specificity of serum laminin for the diagnosis of neoplastic ascites.
  • When compared to the group with cirrhosis, the carcinomatosis group presented significantly higher mean laminin levels in serum (3.3 +/- 0.5 vs 2.1 +/- 0.4 microg/ml, mean +/- SD, P < 0.05) and ascites (2.8 +/- 0.5 vs 1.6 +/- 0.4 microg/ml, P < 0.05).
  • Serum laminin levels >2.25 microg/ml showed 100% sensitivity and 73% specificity for the diagnosis of neoplastic ascites.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785839.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin
  •  go-up   go-down


24. Grira MT, Ben Jemaa HM, Lammouchi TM, Benammou SA: Meningitis revealing pancreatic carcinoma. Neurosciences (Riyadh); 2007 Jul;12(3):256-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal carcinomatosis is an uncommon metastatic complication of systemic solid tumors.
  • The diagnosis is based on the presence of malignant cells in the cerebrospinal fluid.
  • Magnetic resonance imaging could help in establishing the diagnosis.
  • The prognosis of carcinomatous meningitis is poor, especially when the primitive neoplasm is initially unknown.
  • Cerebrospinal fluid analysis showed malignant cells consistent with an adenocarcinoma.
  • Abdominal echography and MRI concluded in a nodule of the cephalic portion of the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21857581.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


25. Hagendoorn J, van Lammeren G, Boerma D, van der Beek E, Wiezer MJ, van Ramshorst B: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival. Eur J Surg Oncol; 2009 Aug;35(8):833-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival.
  • BACKGROUND: Peritoneal carcinomatosis from colorectal origin carries a poor prognosis.
  • Recent clinical studies show that cytoreductive surgery (CS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival of selected patients with a colorectal carcinoma and isolated peritoneal carcinomatosis in the absence of extra-abdominal metastases.
  • All had peritoneal carcinomatosis originating from primary colorectal, cecal, appendiceal, and gastric tumors.
  • The overall morbidity was 43%, including extended gastroparesis (11%), anastomotic failure (11%) and intra-abdominal abscess (9%).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Colorectal Neoplasms / pathology. Gastrointestinal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019619.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Chang K, Ko WC, Li BF, Liu PY, Chiu NT: Diffuse abdominal uptake mimicking peritonitis in gallium inflammatory scan: an unusual feature of acute Q fever. Kaohsiung J Med Sci; 2005 Nov;21(11):522-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse abdominal uptake mimicking peritonitis in gallium inflammatory scan: an unusual feature of acute Q fever.
  • We present a patient with fever, abdominal distension, pericardial effusion, and diffuse gallium uptake in the abdominal cavity, mimicking peritonitis or peritoneum carcinomatosis.
  • During the afebrile period, gallium inflammatory scan showed resolution of previous diffuse uptake in the abdomen, and cardiac echo resolution of pericardial effusion, which was suggestive of peritoneal inflammation related to acute C. burnetii infection.
  • Therefore, clinicians in Taiwan should be alert to the possibility of acute Q fever in patients with fever of unknown cause, especially with clinical evidence of peritoneal and/or pericardial inflammation.
  • [MeSH-major] Abdominal Cavity / radionuclide imaging. Gallium Radioisotopes. Peritonitis / radionuclide imaging. Q Fever / radionuclide imaging

  • Genetic Alliance. consumer health - Q fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358555.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Gallium Radioisotopes
  •  go-up   go-down


27. Esquivel J, Merriman B, Davis S, Manning D: Appendiceal cancer and peritoneal carcinomatosis: a report of 29 cases. Am Surg; 2006 Aug;72(8):714-7; discussion 717-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal cancer and peritoneal carcinomatosis: a report of 29 cases.
  • Peritoneal surface malignancies of appendiceal origin arise from a perforated neoplasm with gradual expansion of the tumor within the abdomen.
  • Between February 2000 and November 2004, 29 patients were classified into one of three groups based on the features of their peritoneal dissemination.
  • Group 1 included those with extracellular mucin with little cellular atypia (disseminated peritoneal adenomucinosis/low-grade mucinous adenocarcinomas).
  • Group 2 included those with peritoneal mucinous carcinomatosis/high-grade mucinous adenocarcinomas, and Group 3 included those with nonmucinous carcinomatosis.
  • Those with mucinous peritoneal dissemination are more likely to benefit from this approach.
  • It appears that in patients with nonmucinous carcinomatosis, the biology of the tumor predicts their outcome.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16913315.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Caricato M, Borzomati D, Ausania F, Garberini A, Rabitti C, Tonini G, Coppola R: Cerebellar metastasis from pancreatic adenocarcinoma. A case report. Pancreatology; 2006;6(4):306-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two years later the patient presented with intractable vomiting, which was attributed to peritoneal carcinomatosis.
  • [MeSH-major] Adenocarcinoma / secondary. Cerebellar Neoplasms / radiography. Cerebellar Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel and IAP.
  • (PMID = 16636605.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


29. Zacharias T, Oussoultzoglou E, Jaeck D, Pessaux P, Bachellier P: Surgery for recurrence of periampullary malignancies. J Gastrointest Surg; 2009 Apr;13(4):760-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with peritoneal carcinomatosis had a median survival of 1.4 month.
  • Peritoneal recurrence was not a good indication for surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] Hepatogastroenterology. 1992 Oct;39(5):429-32 [1459525.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):566-72 [17414605.001]
  • [Cites] Strahlenther Onkol. 2003 Feb;179(2):87-92 [12590318.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):490-5 [11169931.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(3):316-20 [10982633.001]
  • [Cites] J Gastrointest Surg. 2005 Feb;9(2):263-9 [15694823.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):350-6 [17458610.001]
  • [Cites] Chir Ital. 2002 Jul-Aug;54(4):539-44 [12239765.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):511-8 [16627216.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] J Nippon Med Sch. 2006 Aug;73(4):226-30 [16936449.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2589-96 [17083124.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4944-50 [15611509.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1321-8 [16211228.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] JOP. 2006 Jan 11;7(1):34-40 [16407616.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 Aug;10(8):703-7 [9744701.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] JOP. 2006 Sep 10;7(5):473-7 [16998244.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(2):174-8 [11455476.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):511-5 [16615155.001]
  • (PMID = 19050979.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Dika E, Balestri R, Vaccari S, Fanti PA, Patrizi A: Peculiar recurrence of malignant melanoma: metastases on cutaneous scars and peritoneal carcinomatosis. Eur J Dermatol; 2010 Sep-Oct;20(5):653-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peculiar recurrence of malignant melanoma: metastases on cutaneous scars and peritoneal carcinomatosis.
  • [MeSH-major] Cicatrix / pathology. Melanoma / surgery. Peritoneal Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20605775.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


31. Aslam MB: Peritoneal lymphomatosis, a morphological look alike to peritoneal carcinomatosis: an autopsy report. J Clin Pathol; 2009 May;62(5):480
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal lymphomatosis, a morphological look alike to peritoneal carcinomatosis: an autopsy report.
  • [MeSH-major] Carcinoma / pathology. Lymphoma, T-Cell / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398600.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


32. Spiliotis JD: Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepatogastroenterology; 2010 Sep-Oct;57(102-103):1173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure.
  • This article offers a review on the use of cytoreductive surgery (CS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis (PC).
  • [MeSH-major] Hyperthermia, Induced. Peritoneal Neoplasms / therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21410053.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Greece
  •  go-up   go-down


33. Martínez A, Querleu D, Leblanc E, Narducci F, Ferron G: Low incidence of port-site metastases after laparoscopic staging of uterine cancer. Gynecol Oncol; 2010 Aug 1;118(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Excluding patients with peritoneal carcinomatosis, the rate of port-site recurrence in our series lowered to 0.16%, and the rate of isolated PSM to 0%.
  • The median time to the development of PSM was 8 months (range 6-48), the median overall survival from diagnosis for all patients was 26 months (range 7-30), and median survival from recurrence was 5 months (range 1-20).
  • [MeSH-major] Endometrial Neoplasms / pathology. Laparoscopy / adverse effects. Neoplasm Seeding. Uterine Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Hysterectomy / adverse effects. Lymph Node Excision / adverse effects. Middle Aged. Neoplasm Staging. Ovariectomy / adverse effects

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20451983.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Sozen I, Small L, Kowalski M, Mayo SW, Hurwitz CA: Adenocarcinoma of the cervix metastatic from a colon primary and diagnosed from a routine pap smear in a 17-year-old woman: a case report. J Reprod Med; 2005 Oct;50(10):793-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequent surgery revealed a sigmoid tumor with extensive abdominal and pelvic carcinomatosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Papanicolaou Test. Sigmoid Neoplasms / diagnosis. Sigmoid Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / secondary. Vaginal Smears


35. Facchiano E, Scaringi S, Kianmanesh R, Sabate JM, Castel B, Flamant Y, Coffin B, Msika S: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol; 2008 Feb;34(2):154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer.
  • AIMS: To review our experience of laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of malignant ascites from advanced gastric cancer in order to discuss benefits, problems and possible indications.
  • METHODS: From June 2000 to May 2003 laparoscopic approach was used to perform HIPEC on five patients affected by malignant ascites secondary to unresectable peritoneal carcinomatosis of gastric origin, in order to associate the benefits of a definitive palliation of ascites with a minimal invasiveness.
  • CONCLUSIONS: Laparoscopic HIPEC appears to be a safe and effective procedure to treat debilitating malignant ascites from unresectable peritoneal carcinomatosis.
  • [MeSH-major] Ascites / therapy. Carcinoma / complications. Chemotherapy, Cancer, Regional Perfusion / methods. Laparoscopy. Palliative Care / methods. Peritoneal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640844.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Adali E, Dulger C, Kolusari A, Kurdoglu M, Yildizhan R: Pelvic-peritoneal tuberculosis simulating peritoneal carcinomatosis: high clinical suspicion and a minimally invasive procedure. Arch Gynecol Obstet; 2009 Nov;280(5):867-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic-peritoneal tuberculosis simulating peritoneal carcinomatosis: high clinical suspicion and a minimally invasive procedure.
  • Peritoneal tuberculosis (TB) is still a major health problem in developing countries.
  • We describe a 26-year-old woman with peritoneal TB presenting with lower abdominal pain and distention, weight loss, and night sweats.
  • There are no pathognomonic clinical, laboratory, or radiologic findings for peritoneal TB.
  • Therefore, it can be easily confused with peritoneal carcinomatosis and advanced ovarian carcinoma.
  • Adenosine deaminase activity in ascitic fluid combined with a high clinic suspicion is an effective and minimally invasive procedure for the differential diagnosis of pelvic-peritoneal TB simulating peritoneal carcinomatosis, and may obviate the need for unnecessary extensive surgery and rapidly initiate appropriate therapy.
  • [MeSH-major] Peritoneal Neoplasms / diagnosis. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Adenosine Deaminase / analysis. Adult. Ascitic Fluid / enzymology. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19565253.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


37. Ströhlein MA, Heiss MM: The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future Oncol; 2010 Sep;6(9):1387-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
  • Peritoneal carcinomatosis remains an unsolved medical problem in modern oncologic treatment.
  • Excruciating symptoms such as malignant ascites, ileus, nausea, vomiting, dyspnoea and pain deteriorate the quality of life for affected patients.
  • There is still no effective standard treatment for peritoneal carcinomatosis.
  • Intraperitoneal catumaxomab therapy was shown to be the first effective therapy against accumulation of malignant ascites in patients with peritoneal carcinomatosis of epithelial cancer, reducing the need of paracentesis and prolonging puncture-free survival.
  • This paper reviews the mode of action of catumaxomab and analyzes different fields of local immunotherapy in patients with peritoneal carcinomatosis.
  • Catumaxomab is discussed to be an outstanding option for local control and therapy of peritoneal carcinomatosis, which could be an optimal modular therapy in addition to systemic chemotherapy and surgical tumor resection.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antineoplastic Agents / therapeutic use. Ascites / drug therapy. Carcinoma / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20919824.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antineoplastic Agents; 0 / catumaxomab
  •  go-up   go-down


38. Spencer JA, Anderson K, Weston M, Wilkinson N, Hewitt M: Image guided biopsy in the management of cancer of the ovary. Cancer Imaging; 2006;6:144-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When used in the context of multidisciplinary team discussion, image guided biopsy using ultrasound (US) or computed tomography (CT) guidance is of value in planning management of women with suspected ovarian cancer and peritoneal carcinomatosis (PC) of uncertain aetiology.
  • It provides a site-specific primary tumour diagnosis in 93% of cases and it should replace diagnostic laparoscopy or laparotomy for this purpose.
  • It allows provision of primary (neoadjuvant) chemotherapy based on a firm histological diagnosis.
  • More women with prior breast cancer who re-present with peritoneal cancer will have a new gynaecological primary than recurrence of their original primary tumour; the two options require radically different therapies.
  • [MeSH-major] Ovarian Neoplasms / pathology. Peritoneum / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) International Cancer Imaging Society.
  • [Cites] Radiology. 2000 Jun;215(3):761-7 [10831697.001]
  • [Cites] Radiology. 2001 Apr;219(1):213-8 [11274559.001]
  • [Cites] Radiology. 2001 Oct;221(1):173-7 [11568336.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):641-55 [1690512.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:108-10 [16515576.001]
  • [Cites] AJR Am J Roentgenol. 1995 Oct;165(4):875-8 [7676985.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):426-9 [8729984.001]
  • [Cites] Mod Pathol. 1996 Nov;9(11):1040-4 [8933513.001]
  • [Cites] Radiology. 1999 Jul;212(1):19-27 [10405715.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • (PMID = 16966069.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1693762
  •  go-up   go-down


39. Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, Vaylet C, Rougier P, André T, Gornet JM, Cherqui D, Delbaldo C, Panis Y, Talbot JN, Meignan M, Le Guludec D: Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer; 2008 Mar 11;98(5):875-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We failed to identify peritoneal carcinomatosis in two of the patients undergoing FDG-PET.
  • [MeSH-major] Colorectal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] BMC Cancer. 2003 Oct 6;3:26 [14529575.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2318-24 [3440238.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] JAMA. 1994 Jul 6;272(1):31 [8007072.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2936-43 [8523058.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):938-46 [9060531.001]
  • [Cites] Gastroenterology. 1998 Jan;114(1):7-14 [9428212.001]
  • [Cites] Ann Intern Med. 1998 Jul 1;129(1):27-35 [9652996.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Abdom Imaging. 2004 Nov-Dec;29(6):663-8 [15162236.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):362-9 [15672427.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2297-303 [16140008.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8512-9 [16260687.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2758-60 [16333012.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2658-70 [16315241.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):386-93 [16365182.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):564-7 [16564155.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3939-45 [16921046.001]
  • [Cites] Am Surg. 2006 Oct;72(10):897-901 [17058730.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jan;188(1):257-67 [17179375.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):432-40 [17139459.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):269-77 [11355141.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):278-85 [11355142.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):388-95 [11786565.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):418-23 [12099653.001]
  • [Cites] Semin Oncol. 2003 Jun;30(3):349-60 [12870136.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] Radiology. 2004 Sep;232(3):815-22 [15273334.001]
  • (PMID = 18301402.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2266857
  •  go-up   go-down


40. Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, Sugarbaker PH: Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol; 2006 Aug;32(6):661-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
  • AIMS: To report our experience of neoadjuvant intraperitoneal and systemic chemotherapy (NIPS) for patients having a complete resection of the primary gastric cancer and peritoneal carcinomatosis (PC).
  • PATIENTS AND METHODS: Patients with advanced peritoneal dissemination of primary gastric cancer had the placement of a peritoneal port system.
  • At surgery a complete removal of the primary gastric cancer and the peritoneal implants by peritonectomy was attempted.
  • CONCLUSION: NIPS can downstage large volume peritoneal dissemination of gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Male. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Quality of Life. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621433.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


41. Turcotte S, Sideris L, Younan R, Drolet P, Dubé P: Pharmacokinetics of intraperitoneal irinotecan in a pig model. J Surg Oncol; 2010 Jun 1;101(7):637-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete surgical cytoreduction of peritoneal implants and immediate intraperitoneal (lP) chemotherapy offers the greatest survival in selected patients with peritoneal carcinomatosis.
  • Systemic venous blood, portal blood and peritoneal fluid samples were taken at 5, 10, 20, 30, and 45 min, then every hour up to 8 hr for the 100 mg.
  • For the three groups, peritoneal CPT-11 exposition was on average 4.9 times greater in the peritoneum than in the systemic venous or portal circulations and the systemic CPT-11 fraction absorbed from the peritoneum linearly increased with time.
  • Free SN-38 was measurable in the earliest peritoneal samples taken.
  • Mean peritoneal SN-38: CPT-11 AUC ratio was 0.043.
  • OPT-11 peritoneal conversion into SN-38 appeared slightly Inferior to the systemic conversion ratio.
  • This norrnothermic IP OPT-11 pharmacokinetic study performed in a pig model confirms the possibility to achieve at least a 30 times higher peritoneal than systemic exposure.
  • Peritoneal exposure to active SN-38 begins at the moment of CPT-11 peritoneal instillation.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Camptothecin / analogs & derivatives. Carcinoma / drug therapy. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20461774.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


42. Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH: Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res; 2007 Feb 15;13(4):1232-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
  • EXPERIMENTAL DESIGN: Patients had peritoneal carcinomatosis.
  • Gemcitabine (40, 80, 120, or 160 mg/m(2)) was administered into the peritoneal cavity in 2 L of warmed saline on days 1, 4, 8, and 12 of a 28-day cycle.
  • The median peak peritoneal concentration was 1,116-fold (range, 456-1,886) higher than the peak plasma level.
  • Plasma and peritoneal levels were undetectable within 8 to 12 h.
  • At 120 mg/m(2), the median peritoneal area under the concentration versus time curve (AUC) was 82,612 ng/mL x h (range, 53,296-199,830) and the plasma AUC was 231 ng/mL x h (range, 47.6-259.5).
  • The mean peritoneal advantage (AUC(peritoneal)/AUC(plasma)) was 847 (range, 356-1,385).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / analogs & derivatives. Peritoneal Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317834.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33572; United States / NCI NIH HHS / CA / CA62505
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


43. Cao C, Yan TD, Black D, Morris DL: A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol; 2009 Aug;16(8):2152-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin.
  • BACKGROUND: The objective of the present meta-analysis was to analyze the survival outcomes of patients with colorectal peritoneal carcinomatosis (CRPC), with particular focus on cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Colorectal Neoplasms / therapy. Peritoneal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434455.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


44. Byrnes K, Li BD, Holm N, Li J, Okadata Y, De Benedetti A, Nedeljkovic-Kurepa A, Mathis M, Chu QD: A novel suicide gene therapy targeting the overexpression of eukaryotic initiation factor 4E improves survival in a rat peritoneal carcinomatosis model. Surgery; 2007 Aug;142(2):270-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel suicide gene therapy targeting the overexpression of eukaryotic initiation factor 4E improves survival in a rat peritoneal carcinomatosis model.
  • We investigated the efficacy of this novel therapy in a rat peritoneal carcinomatosis (PC) model.
  • CONCLUSIONS: Treatment with a novel suicide gene therapy following cytoreductive surgery prolonged survival in a rat peritoneal carcinomatosis model.
  • [MeSH-major] Adenocarcinoma / therapy. Eukaryotic Initiation Factor-4E / genetics. Genes, Transgenic, Suicide. Genetic Therapy / methods. Mammary Neoplasms, Animal / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adenoviridae / genetics. Animals. Antiviral Agents / pharmacology. Cell Line, Tumor. Combined Modality Therapy. Disease Models, Animal. Female. Ganciclovir / pharmacology. Gene Expression Regulation, Neoplastic. Neoplasm Transplantation. Neoplasm, Residual / surgery. Neoplasm, Residual / therapy. Omentum. Rats. Rats, Inbred F344. Survival Rate

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689695.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Eukaryotic Initiation Factor-4E; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


45. Belval CC, Barranger E, Dubernard G, Touboul E, Houry S, Daraï E: Peritoneal carcinomatosis after laparoscopic radical hysterectomy for early-stage cervical adenocarcinoma. Gynecol Oncol; 2006 Sep;102(3):580-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis after laparoscopic radical hysterectomy for early-stage cervical adenocarcinoma.
  • BACKGROUND: The risk of wound metastasis after laparoscopic management of early-stage cervical cancer is well known, but there are few data on peritoneal carcinomatosis of cervical adenocarcinoma.
  • CASE: We report the first case of peritoneal carcinomatosis occurring in a woman with FIGO stage Ib1 cervical adenocarcinoma who underwent laparoscopic type III radical hysterectomy and bilateral pelvic lymphadenectomy (sentinel node procedure) followed by vaginal brachytherapy.
  • A peritoneal recurrence was diagnosed 16 months after surgery and was treated with chemotherapy and laparotomy.
  • CONCLUSION: Laparoscopy for cervical adenocarcinoma may carry a risk of peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma / surgery. Hysterectomy. Peritoneal Neoplasms / secondary. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624387.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Markman M, Belinson J: A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. J Cancer Res Clin Oncol; 2005 Jan;131(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
  • PURPOSE: Optimal management of patients with advanced ovarian or primary peritoneal cancers who have received, and achieved an excellent response to, neoadjuvant chemotherapy remains undefined.
  • METHODS: Five patients are briefly presented who were found to have extensive intra-abdominal carcinomatosis from ovarian/peritoneal cancers and were initially treated with a carboplatin/paclitaxel-based neoadjuvant chemotherapy program.
  • RESULTS AND CONCLUSION: In the absence of definitive data from randomized phase-3 trials defining optimal management in this setting, a rational argument can be provided supporting the use of this multi-modality management strategy (neoadjuvant chemotherapy followed by surgery and regional chemotherapy) in carefully selected patients presenting with extensive ovarian or primary peritoneal cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Nov 15;92(10):2585-91 [11745193.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):694-8 [11821450.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1479-84 [1517791.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):57-60 [3277734.001]
  • [Cites] Gynecol Oncol. 1998 May;69(2):103-8 [9600815.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2329-34 [11413522.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(6):389-94 [2311166.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3380-4 [2720692.001]
  • [Cites] Cancer Treat Rep. 1983 Dec;67(12):1085-92 [6228294.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1):9-16 [12504620.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):269-74 [10985879.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18(3):235-8 [3542268.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] Cancer Treat Rep. 1983 Mar;67(3):235-8 [6682012.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70 [11906550.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):93-9 [9889037.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):351-5 [11972399.001]
  • [Cites] Gynecol Oncol. 1998 Apr;69(1):17-22 [9570993.001]
  • [Cites] Ann Intern Med. 1982 Dec;97(6):845-51 [6890785.001]
  • [Cites] AJR Am J Roentgenol. 1995 Oct;165(4):875-8 [7676985.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1801-5 [1919630.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • (PMID = 15449183.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


47. Ruiz-Tovar J, Morales Castiñeiras V, García Teruel D, Sanjuanbenito Dehesa A, Lobo Martínez E, Martínez Molina E: Pseudomyxoma peritonei secondary to epithelial appendicular neoplasms. Experience in a non-specialised centre. Clin Transl Oncol; 2007 Nov;9(11):737-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei secondary to epithelial appendicular neoplasms. Experience in a non-specialised centre.
  • INTRODUCTION: Pseudomyxoma peritonei is an infrequent entity, defined by collections of gelatinous material in the abdomen and pelvis and mucinous implants on peritoneum, secondary to the rupture of a mucinous lesion, usually of ovarian or appendiceal origin.
  • MATERIALS AND METHODS: We present our experience of 11 cases (6 males and 5 females) diagnosed with pseudomyxoma peritonei secondary to epithelial appendicular neoplasms over 27 years.
  • Clinical manifestations were abdominal distension (55%), right lower quadrant pain (45%) suggesting acute appendicitis and constitutional syndrome (36%).
  • An abdominal mass was detected at physical examination in 4 patients.
  • CT scan revealed a tumour in right iliac fossa in 4 patients, peritoneal enlargement in 1 and a liquid collection in 1.
  • Preoperative diagnosis was acute abdomen in 5 patients, peritoneal carcinomatosis in 3 and undetermined abdominal mass in 3.
  • RESULTS: Surgical findings suggested pseudomyxoma peritonei in 8 patients and peritoneal carcinomatosis in 3.
  • The last case we treated was sent to a reference centre for the treatment of pseudomyxoma peritonei.
  • CONCLUSIONS: There is no consensus on the best treatment for pseudomyxoma peritonei.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / pathology. Epithelial Cells / pathology. Neoplasms, Multiple Primary / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1089-103 [12883241.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] Ann Surg. 2005 Nov;242(5):748-50; author reply 750-1 [16244553.001]
  • [Cites] Dis Colon Rectum. 2007 Jan;50(1):37-42 [17115339.001]
  • [Cites] World J Surg. 2007 Mar;31(3):542-8 [17318706.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1332-9 [9782010.001]
  • (PMID = 18055329.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Gómez Portilla A, Cendoya I, Olabarría I, Martínez de Lecea C, Gómez Martínez de Lecea C, Gil A, Martín E, Muriel J, Magrach L, Romero E, Lirola A, Guede N, Moraza N, Fernández E, Kvadatze M, Valdovinos M, Larrabide I, Ruiz de Alegría N, Fernández JL, Castillo C, Rua O, Ulibarrena MA: The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis. Rev Esp Enferm Dig; 2009 Feb;101(2):97-102, 103-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
  • PH Sugarbaker, challenging oncological orthodoxy, considered carcinomatosis to be a locoregional stage of the disease that was still susceptible to treatment with curative intent.
  • The macroscopic disease treated by maximum radical oncological cytoreductive surgery (through the peritonectomies described by him), followed by treatment of the residual microscopic disease with the direct intra-abdominal application of intraoperative chemotherapy with locoregional intensification, modulated by hyperthermia and early normothermic postoperative intra-abdominal chemotherapy.
  • Using this new therapeutic regimen, known as "Sugarbaker s Protocol", his group has reported 45% survival rates in carcinomatosis of colorectal origin at 5 years, and, in selected groups of patients, 50% survival rates at 5 years.
  • Various European groups have replied to these main criticisms confirming the good results that this new therapeutic alternative offers for patients with carcinomatosis of colorectal origin.
  • MATERIAL AND METHODS: All the articles published in the English language by European groups in the world s medical literature have been reviewed using the Pubmed-MEDLINE database to identify the relevant articles related to the treatment of carcinomatosis of colorectal origin using cytoreduction and intraperitoneal chemotherapy from January 1980 to January 2008.
  • At the same time, two new transcendental European contributions have been made in which the possibility has been considered of combined simultaneous treatment for patients with hepatic metastases and carcinomatosis, and the introduction, as a selection factor, of patients responsive to intravenous induction chemotherapy within the regimen of sandwich treatment (with systemic neoadjuvant and adjuvant chemotherapy) complementary to intraperitoneal chemotherapy.
  • CONCLUSIONS: The results obtained by European groups using "Sugarbaker s protocol" and "Elias protocol" with oxaliplatin compel us to request that these treatments be considered by all professionals involved in the treatment of patients with colorectal carcinomatosis as the best treatment currently available for this condition.
  • A validation of this treatment will change, in the future, the dogmatic consideration of carcinomatosis as an incurable disease stage.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant / statistics & numerical data. Clinical Trials, Phase III as Topic / statistics & numerical data. Combined Modality Therapy. Europe / epidemiology. Fluorouracil / administration & dosage. Humans. Hyperthermia, Induced. Infusions, Parenteral. Liver Neoplasms / secondary. Multicenter Studies as Topic / statistics & numerical data. Neoadjuvant Therapy / statistics & numerical data. Organoplatinum Compounds / administration & dosage. Randomized Controlled Trials as Topic / statistics & numerical data. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335045.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 54
  •  go-up   go-down


49. Liberale G, Pocard M, Manganas D, Ducreux M, Lasser P, Elias D: Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of digestive and peritoneal origin: rationale. Acta Chir Belg; 2006 May-Jun;106(3):291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of digestive and peritoneal origin: rationale.
  • Up to a few years ago peritoneal carcinomatosis was considered as an "incurable" disease.
  • The aim of this paper is to review the surgical approach with curative intent to carcinomatosis: it consists of complete resection of macroscopic disease (R1), associated with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat residual microscopic disease, and to evaluate its indications.
  • Overall 5-year survival of patients with peritoneal carcinomatosis treated by HIPEC is similar to that of patients with hepatic metastases treated with curative intent.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910001.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 49
  •  go-up   go-down


51. Bijelic L, Jonson A, Sugarbaker PH: Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol; 2007 Dec;18(12):1943-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer.


52. Koppe MJ, Oyen WJ, Bleichrodt RP, Hendriks T, Verhofstad AA, Goldenberg DM, Boerman OC: Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Immunol Immunother; 2006 Jan;55(1):47-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
  • The aim of this study was to investigate whether the efficacy of radioimmunotherapy (RIT) using 131I-labeled anti-CEA monoclonal antibody MN-14 could be enhanced by co-administration of the selective COX-2 inhibitor Parecoxib in mice with small volume (1-3 mm) peritoneal carcinomatosis of colonic origin.
  • CONCLUSION: The COX-2 inhibitor Parecoxib does not enhance the therapeutic efficacy of RIT of experimental small volume peritoneal carcinomatosis of colonic origin.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Colonic Neoplasms / pathology. Cyclooxygenase Inhibitors / therapeutic use. Isoxazoles / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868166.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclooxygenase Inhibitors; 0 / Iodine Radioisotopes; 0 / Isoxazoles; 9TUW81Y3CE / parecoxib
  •  go-up   go-down


53. Stewart JH 4th, Shen P, Levine EA: Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Expert Rev Anticancer Ther; 2008 Nov;8(11):1809-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies.
  • Many intra-abdominal malignancies spread throughout the peritoneal cavity, which is known as carcinomatosis.
  • Peritoneal carcinomatosis is uniformly a terminal disease with a median survival of 6 months.
  • However, cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy (IPHC) has evolved into a novel approach for peritoneal surface malignancy.
  • Although the first clinical series of peritoneal perfusion were small, Japanese trials, which utilized IPHC for prophylaxis in patients with gastric adenocarcinoma, Fujimoto was the first to report an improvement in survival for established gastric cracinomatosis.
  • The present review will outline the rationale, current practice and future directions of IPHC in the management of peritoneal surface malignancies.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / trends. Hyperthermia, Induced / trends. Peritoneal Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983241.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA131482
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 75
  •  go-up   go-down


54. Füzün M, Sökmen S, Terzi C, Canda AE: Cytoreductive approach to peritoneal carcinomatosis originated from colorectal cancer: Turkish experience. Acta Chir Iugosl; 2006;53(2):17-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive approach to peritoneal carcinomatosis originated from colorectal cancer: Turkish experience.
  • Peritoneal carcinomatosis (PC) in contrast to lymph nodes and liver metastases was assumed as a terminal condition with no curative treatment options having a 5 to 9 months median survival rate until recently.
  • Mean survival time was 56 months in patients with peritoneal cancer index (PCI) < 10, and 22 months in patients with PCI > 10 (P = 0.075).
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139879.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


55. Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, Miura M, Ikeda M, Ikeda S, Nakajima G, Yonemura J, Yuuba T, Masuda S, Kimura H, Matsuki N: Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol; 2009 Sep 15;100(4):311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery.
  • There is no standard treatment for peritoneal carcinomatosis (PC) from gastric cancer.
  • A peritoneal port system was introduced into the abdominal cavity.
  • The peritoneal wash cytological examination through a port was done before and after NIPS.
  • On day 1, 8, and 15 from the start of oral TS-1 administration, 30 mg/m(2) of Docetaxel and 30 mg/m(2) of cisplatinum with 500 ml of saline were introduced into the peritoneal cavity through the port.
  • Peritoneal free cancer cells (PFCCs) had been detected in 65 (82.2%) patients before NIPS, and the positive cytology changed to be negative in 41 (63.0%) patients after NIPS.
  • Peritoneal wash cytology through a port system is a good indicator to select the patients to perform cytoreductive surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Neoplasm Recurrence, Local / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Patient Selection. Prognosis. Survival Rate. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19697437.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


56. Yan TD, Chu F, Links M, Kam PC, Glenn D, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol; 2006 Dec;32(10):1119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival.
  • AIMS: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has been reported as a treatment option for patients with peritoneal carcinomatosis from colorectal carcinoma.
  • METHODS: Thirty patients with colorectal peritoneal carcinomatosis underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy.
  • Univariate analysis demonstrated that patients with non-mucinous colorectal adenocarcinoma, Peritoneal Cancer Index (PCI) < or =13, and complete cytoreduction were associated with an improved survival.
  • CONCLUSIONS: This study reported on 30 patients who underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / therapy. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887321.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


57. Bouquet W, Boterberg T, Ceelen W, Pattyn P, Peeters M, Bracke M, Remon JP, Vervaet C: In vitro cytotoxicity of paclitaxel/beta-cyclodextrin complexes for HIPEC. Int J Pharm; 2009 Feb 9;367(1-2):148-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising strategy in the treatment of peritoneal carcinomatosis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Drug Carriers / chemistry. Hyperthermia, Induced / methods. Paclitaxel / pharmacology. Peritoneal Neoplasms / therapy. beta-Cyclodextrins / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18938234.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Carriers; 0 / Excipients; 0 / beta-Cyclodextrins; JV039JZZ3A / betadex; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


58. Schima W, Ba-Ssalamah A, Kölblinger C, Kulinna-Cosentini C, Puespoek A, Götzinger P: Pancreatic adenocarcinoma. Eur Radiol; 2007 Mar;17(3):638-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinoma is the most common malignant pancreatic tumor, affecting the head of the pancreas in 60-70% of cases.
  • By the time of diagnosis, at least 80% of tumors are unresectable.
  • Moreover, it is not very accurate for determining nonresectability because small liver metastases, peritoneal carcinomatosis, and subtle signs of vascular infiltration may be missed.
  • It is the technique of choice for image-guided biopsy if a histologic diagnosis is required for further therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Contrast Media. Endosonography. Humans. Magnetic Resonance Imaging. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Mar;214(3):849-55 [10715057.001]
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] Eur Radiol. 2004 Jan;14(1):14-20 [14730384.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):218-24 [12145600.001]
  • [Cites] Abdom Imaging. 1997 Jul-Aug;22(4):429-33 [9157866.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10 ):753-63 [15545675.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Abdom Imaging. 1997 Mar-Apr;22(2):204-7 [9013536.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):700-3 [16120921.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Pancreatology. 2001;1(6):610-24 [12120244.001]
  • [Cites] AJR Am J Roentgenol. 1998 Mar;170(3):649-52 [9490946.001]
  • [Cites] Eur Radiol. 2005 Nov;15 Suppl 4:D96-9 [16479656.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):231-4 [11246351.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Radiology. 1997 Nov;205(2):513-8 [9356637.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1410-27 [15499648.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):118-26; discussion 127-8 [12559193.001]
  • [Cites] Radiology. 1991 Aug;180(2):337-9 [1906189.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] Br J Radiol. 2000 Nov;73(875):1165-9 [11144793.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Radiology. 1993 Mar;186(3):795-8 [8430190.001]
  • [Cites] Radiographics. 2005 Jul-Aug;25(4):949-65 [16009817.001]
  • [Cites] Radiology. 2001 Oct;221(1):107-16 [11568327.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1513-8 [10584794.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Eur Radiol. 2005 Jun;15(6):1256-62 [15627187.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Radiology. 1996 Jun;199(3):697-701 [8637990.001]
  • [Cites] Invest Radiol. 1999 Sep;34(9):589-95 [10485075.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):494-504 [7960219.001]
  • [Cites] Br J Radiol. 1998 May;71(845):492-6 [9691893.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 5:M42-9 [14989611.001]
  • [Cites] Radiology. 2002 Dec;225(3):759-65 [12461258.001]
  • [Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jul;169(1):119-23 [9207510.001]
  • [Cites] Radiology. 1991 Jan;178(1):95-9 [1984331.001]
  • [Cites] Eur Radiol. 1996;6(1):14-8 [8797944.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):677-84 [10701608.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12 ):2658-61 [16393216.001]
  • [Cites] Eur Radiol. 2002 Dec;12(12):2998-3008 [12439582.001]
  • [Cites] Radiology. 2006 Nov;241(2):441-8 [16982815.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):419-25 [14736675.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):230-3 [2154172.001]
  • [Cites] Radiologe. 2006 May;46(5):421-37; quiz 438 [16715226.001]
  • [Cites] Radiology. 1997 Mar;202(3):655-62 [9051012.001]
  • [Cites] J Magn Reson Imaging. 2000 Aug;12 (2):261-8 [10931589.001]
  • [Cites] Radiology. 1995 May;195(2):327-32 [7724748.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):738-45 [15492552.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] World J Surg. 1999 Sep;23(9):913-9 [10449820.001]
  • [Cites] Rofo. 2004 Nov;176(11):1624-33 [15497081.001]
  • [Cites] J Comput Assist Tomogr. 2002 Sep-Oct;26(5):743-9 [12439309.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • (PMID = 17021700.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 65
  •  go-up   go-down


59. Zorrón R, Soldan M, Filgueiras M, Maggioni LC, Pombo L, Oliveira AL: NOTES: transvaginal for cancer diagnostic staging: preliminary clinical application. Surg Innov; 2008 Sep;15(3):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a 50-year-old female patient presenting with ascitis, diffuse abdominal pain, and weight loss for 2 months, diagnosis of peritoneal carcinomatosis was suspected, which was also found when a CT scan was performed.
  • Biopsies of liver, diaphragm, ovaries, and peritoneum were successfully performed.
  • Abdominal inventory was reliable, and all 16 biopsies taken were positive for ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endoscopy / methods. Endoscopy / trends. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Colonoscopes. Female. Humans. Laparoscopy. Middle Aged. Neoplasm Staging / methods. Pneumoperitoneum, Artificial

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614547.001).
  • [ISSN] 1553-3506
  • [Journal-full-title] Surgical innovation
  • [ISO-abbreviation] Surg Innov
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Bucher M, Pusztaszeri M, Bouzourene H: [Leiomyomatosis peritonealis disseminata: immunohistochemical profile and origin]. Ann Pathol; 2006 Jun;26(3):207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leiomyomatosis peritonealis disseminata: immunohistochemical profile and origin].
  • [Transliterated title] La léiomyomatose péritonéale disséminée: profil immunohistochimique et origine.
  • Leiomyomatosis peritonealis disseminata (LPD) is a rare disease presenting as multiple peritoneal nodules of smooth muscle cells, mimicking peritoneal carcinomatosis.
  • At term, she had an elective caesarean section during which several firm peritoneal nodules, ranging from 0.2 to 0.4 mm, were found.
  • [MeSH-major] Leiomyoma / pathology. Peritoneal Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127852.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


61. Hwangbo Y, Jung JH, Shim J, Kim BH, Jung SH, Lee CK, Jang JY, Dong SH, Kim HJ, Chang YW, Chang R: [Etiologic and laboratory analyses of ascites in patients who underwent diagnostic paracentesis]. Korean J Hepatol; 2007 Jun;13(2):185-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Liver cirrhosis and malignant tumors are two major causes of ascites according to the reports from Western countries, 80% and 10% respectively.
  • Among cancer-related ascites, peritoneal carcinomatosis type was 75.5% (primary sites: stomach 24.5%, pancreas 15.9%, colon 15.9%, lung 7.4%, etc), metastatic liver cancers 8.5%, hepatocellular carcinoma without cirrhosis 6.4%, etc.
  • The sensitivity of serum-ascites albumin gradient for the diagnosis of cirrhotic ascites was 91.4%, and total protein in ascites also revealed a comparable diagnostic sensitivity, 90%.
  • [MeSH-major] Liver Cirrhosis / diagnosis. Liver Cirrhosis, Alcoholic / diagnosis. Neoplasms / diagnosis. Paracentesis. Peritonitis, Tuberculous / diagnosis

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585192.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


62. Karakoc D, Memis A, Sayek I: Intestinal obstructions: what has changed so far? Int Surg; 2009 Oct-Dec;94(4):344-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with peritoneal carcinomatosis constituted 3.26% of the patients in group I and 27.03% of the patients in group II (P = 0.0001).
  • Abdominal computed tomography was not used in the first group and was used in 60.54% of those in the second group (P = 0.0001).
  • Intestinal obstruction due to peritoneal carcinomatosis seems to be a growing problem.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Diagnostic Imaging. Female. Humans. Intestinal Neoplasms / complications. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / surgery. Male. Middle Aged. Postoperative Complications / epidemiology. Retrospective Studies. Risk Factors. Treatment Outcome. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302033.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Lang SA, Glockzin G, Dahlke MH, Popp FC, Agha A, Schlitt HJ, Piso P: [The techniques of peritonectomy and hyperthermic intraperitoneal chemotherapy]. Zentralbl Chir; 2009 Sep;134(5):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of peritoneal carcinomatosis represents a challenge in the therapy for gastrointestinal cancer.
  • Patients with peritoneal carcinomatosis should be evaluated by an interdisciplinary team concerning this multimodal therapy option and, if applicable, they should be referred to therapy within the framework of clinical studies.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / surgery. Hyperthermia, Induced / methods. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Aged. Cancer Care Facilities. Chemotherapy, Adjuvant. Cholecystectomy. Colon, Sigmoid / surgery. Combined Modality Therapy. Female. Gastrectomy. Humans. Male. Middle Aged. Omentum / surgery. Patient Selection. Peritoneum / surgery. Prognosis. Pseudomyxoma Peritonei / drug therapy. Pseudomyxoma Peritonei / mortality. Pseudomyxoma Peritonei / surgery. Referral and Consultation. Splenectomy. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag Stuttgart-New York.
  • (PMID = 19492282.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


64. Kodera Y, Ito S, Mochizuki Y, Yamamura Y, Misawa K, Ohashi N, Nakayama G, Koike M, Fujiwara M, Nakao A: The number of metastatic lymph nodes is a significant risk factor for bone metastasis and poor outcome after surgery for linitis plastica-type gastric carcinoma. World J Surg; 2008 Sep;32(9):2015-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although a prominent pattern of disease failure is peritoneal carcinomatosis, some patients experience rapid disease progression without signs of the peritoneal disease.
  • Peritoneal carcinomatosis was observed in 131 patients and was the commonest pattern of recurrence.
  • CONCLUSION: Treatment strategy for the linitis plastica should in general combine surgery with aggressive treatment directed toward peritoneal disease.
  • [MeSH-major] Bone Neoplasms / secondary. Linitis Plastica / pathology. Linitis Plastica / surgery. Lymphatic Metastasis / pathology. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Chi-Square Distribution. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Proportional Hazards Models. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):960-3 [17591103.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):532-6 [7676695.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2053-62 [2680049.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1642-7 [17133268.001]
  • [Cites] Cancer. 1993 May 15;71(10):2918-25 [8490819.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):434-7 [10022642.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):20-6 [14718269.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):513-29 [15297943.001]
  • [Cites] Gastric Cancer. 2007;10(1):58-62 [17334720.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):112-7 [7844980.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] World J Surg. 1987 Aug;11(4):418-25 [3630186.001]
  • [Cites] Surgery. 1996 Apr;119(4):437-44 [8644010.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] J Am Coll Surg. 1996 Nov;183(5):480-5 [8912617.001]
  • [Cites] Gastric Cancer. 2007;10(1):29-34 [17334715.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):219-28 [15050953.001]
  • [Cites] Jpn J Clin Oncol. 2004 Sep;34(9):525-31 [15466826.001]
  • [Cites] Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-2):1249-55 [3382198.001]
  • [Cites] Br J Surg. 1988 Feb;75(2):116-9 [3349295.001]
  • (PMID = 18563480.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Bailly C, Bailly-Glatre A, Alfidja A, Vincent C, Dauplat J, Pomel C: [Peritoneal carcinosis in ovarian cancer: conventional imaging (CT-scan and MRI)]. Bull Cancer; 2009 Dec;96(12):1155-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal carcinosis in ovarian cancer: conventional imaging (CT-scan and MRI)].
  • [Transliterated title] Imagerie conventionnelle << péritonéale >> des cancers de l'ovaire (scanner, IRM).
  • Ovarian cancer is usually diagnosed at an advanced stage with peritoneal extension which often occurs early on.
  • Imaging plays an important role in the pretherapeutic assessment of peritoneal extension.
  • Carcinomatosis involving the hepatic hilum, the cavo-supra-hepatic confluence, the mesentery, and/or the intestinal wall precludes optimal surgery and may be an indication for neoadjuvant chemotherapy.
  • Abdominal and pelvic MDCT scan is the best imaging technique for the preoperative staging of peritoneal carcinomatosis.
  • Conventional imaging however sometimes underestimates peritoneal carcinomatosis and therefore cannot always be a substitute for surgical staging.
  • [MeSH-major] Carcinoma / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Ascitic Fluid / physiology. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness / pathology. Tomography, X-Ray Computed. Ultrasonography / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959422.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


66. Nestler G, Schulz HU, Tautenhahn J, Kuhn R, Krüger S, Lippert H, Pross M: Effects of the angiogenesis inhibitor angiostatin on the growth of CC531 colon carcinoma cells in vitro and in a laparoscopic animal model of peritoneal carcinomatosis. Int J Colorectal Dis; 2006 May;21(4):314-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the angiogenesis inhibitor angiostatin on the growth of CC531 colon carcinoma cells in vitro and in a laparoscopic animal model of peritoneal carcinomatosis.
  • We investigated the cytotoxic, anti-adhesive, and anti-invasive effects of angiostatin in vitro and on intraperitoneal tumor growth in a laparoscopic rat model of peritoneal carcinomatosis using CC531 colon adenocarcinoma cells.
  • After 21 days, the animals were euthanized to determine the intra-abdominal tumor weight.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Angiostatins / pharmacology. Neovascularization, Pathologic / prevention & control. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Animals. Cell Adhesion / drug effects. Cell Line, Tumor / drug effects. Colonic Neoplasms / pathology. Disease Models, Animal. Dose-Response Relationship, Drug. Injections, Intraperitoneal. Injections, Subcutaneous. Laparoscopy. Male. Neoplasm Transplantation. Pneumoperitoneum, Artificial. Random Allocation. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):63-70 [11245282.001]
  • [Cites] Invasion Metastasis. 1989;9(3):192-208 [2722434.001]
  • [Cites] Nat Med. 1995 Feb;1(2):149-53 [7585012.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4025-33 [14519623.001]
  • [Cites] Br J Biomed Sci. 2002;59(1):11-4 [12000178.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4730-41 [9845539.001]
  • [Cites] World J Surg. 2003 Apr;27(4):405-11 [12658482.001]
  • [Cites] Semin Cancer Biol. 2003 Apr;13(2):159-67 [12654259.001]
  • [Cites] Surgery. 2005 Feb;137(2):246-9 [15674209.001]
  • [Cites] Nature. 1997 Nov 27;390(6658):404-7 [9389480.001]
  • [Cites] Endothelium. 2002;9(1):3-10 [12901356.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):382-7 [11238700.001]
  • [Cites] Oncology. 1997 May-Jun;54(3):177-84 [9143396.001]
  • [Cites] Langenbecks Arch Surg. 1999 Apr;384(2):133-40 [10328166.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Important Adv Oncol. 1985;:42-62 [2453453.001]
  • [Cites] In Vivo. 2001 May-Jun;15(3):233-8 [11491018.001]
  • [Cites] Lancet. 1994 Jul 2;344(8914):58 [7912321.001]
  • [Cites] Cancer Gene Ther. 2004 Sep;11(9):625-32 [15338011.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Br J Cancer. 2005 Feb 28;92(4):729-35 [15700042.001]
  • [Cites] P R Health Sci J. 2003 Jun;22(2):149-51 [12866139.001]
  • [Cites] Langenbecks Arch Surg. 1999 Apr;384(2):167-75 [10328170.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1329-34 [9102221.001]
  • [Cites] Surg Endosc. 2002 Mar;16(3):441-5 [11928024.001]
  • [Cites] Exp Mol Pathol. 2003 Oct;75(2):119-23 [14516772.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):181-90 [11191058.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2566-70 [7684319.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):406-14 [9843599.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4275-80 [12874037.001]
  • [Cites] Drugs Today (Barc). 2001 Dec;37(12):815-821 [12734604.001]
  • (PMID = 16205930.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 86090-08-6 / Angiostatins
  •  go-up   go-down


67. Marin K, Oleszewski K, Muehlbauer P: Intraperitoneal chemotherapy: implications beyond ovarian cancer. Clin J Oncol Nurs; 2007 Dec;11(6):881-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local-regional chemotherapy potentially is an ideal treatment for local spread of those peritoneal carcinomas.
  • This article focuses on nursing management strategies for patients receiving IP chemotherapy for ovarian cancer and other peritoneal carcinomatosis.
  • [MeSH-minor] Catheters, Indwelling. Clinical Trials as Topic. Drug Monitoring / methods. Drug Monitoring / nursing. Female. Humans. Information Services. Infusions, Intravenous / nursing. Internet. National Cancer Institute (U.S.). Patient Care Planning. Patient Education as Topic. Peritoneal Dialysis / instrumentation. Practice Guidelines as Topic. United States

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063547.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


68. Folprecht G, Köhne CH, Lutz MP: Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Cancer Treat Res; 2007;134:425-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633071.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 57
  •  go-up   go-down


69. Zhao DB, Shan Y, Wang CF, Wu JX, Shao YF, Zhao P: [Surgical treatment for colorectal cancer with simultaneous hepatic metastasis]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):552-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis showed that liver metastasis resection, abdominal carcinomatosis, chemotherapy and intervention treatment were the most important prognostic factors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colectomy / methods. Female. Follow-Up Studies. Hepatectomy / methods. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Rectum / surgery. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069642.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Roviello F, Pedrazzani C, Marrelli D, Neri A, Caruso S, Rampone B, Corso G, De Stefano A, Pinto E: [Surgical treatment of gastric cancer]. Chir Ital; 2008 May-Jun;60(3):367-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review examines the different issues related to the surgical treatment of early and advanced gastric adenocarcinoma as well as the most recent strategies for the treatment and prevention of peritoneal carcinomatosis.
  • [MeSH-minor] Humans. Lymph Node Excision. Lymphatic Metastasis. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709775.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 99
  •  go-up   go-down


71. Ben-Arie A, Huszar M, Ben-Zvi N, Smirnov A, Altevogt P, Fogel M: The role of L1-CAM immunohistochemial staining in the diagnosis of abdominal-pelvic cancer of uncertain primary site in women. Eur J Surg Oncol; 2008 Jul;34(7):795-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of L1-CAM immunohistochemial staining in the diagnosis of abdominal-pelvic cancer of uncertain primary site in women.
  • Here we evaluated whether L1-CAM could serve as a novel tumor marker for the diagnosis of metastatic abdominal-pelvic cancers of uncertain origin in women.
  • PATIENTS AND METHODS: During a 6-year period we investigated 28 patients with metastatic abdominal or pelvic cancer with uncertain primary-origin.
  • RESULTS: In 20 patients where the differential diagnosis was primary ovarian or endometrial cancer and primary or recurrent colon cancer, L1 immunohistochemistry staining allowed or supported the correct diagnosis.
  • In four cases L1 staining allowed the correct diagnosis between breast and ovarian cancer.
  • In two cases vaginal metastases of unknown origin were positive to L1 immunohistochemistry staining implying their mullerian origin and one case each of inguinal lymph node metastases and abdominal wall cancer that were positive for L1-CAM, allowed the correct diagnosis of primary ovarian cancer.
  • In a whole, L1-CAM was of crucial role of delinating the final diagnosis in 17 of the 28 cases described.
  • Its incorporation into the conventional immunohistochemistry analysis in cases of cancer of unknown primary in women, allows a correct diagnosis and subsequent treatment in the majority of cases with abdominal-pelvic carcinomatosis.
  • [MeSH-major] Abdominal Neoplasms / pathology. Biomarkers, Tumor / metabolism. Neoplasms, Unknown Primary / pathology. Neural Cell Adhesion Molecule L1 / metabolism. Pelvic Neoplasms / pathology
  • [MeSH-minor] Case-Control Studies. Diagnosis, Differential. Endometrial Neoplasms / pathology. Endometrial Neoplasms / secondary. Female. Humans. Immunohistochemistry. Mullerian Ducts. Ovarian Neoplasms / pathology. Ovarian Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845837.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


72. Idris T, Winter R, Lang U, Petru E: Topotecan-induced long-term remission of an advanced endometrial cancer after treatment with cisplatinum, an anthracycline and paclitaxel. Anticancer Res; 2009 May;29(5):1761-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three months thereafter, computed tomography showed diffuse peritoneal carcinomatosis with lesions up to 2 cm in diameter.
  • CONCLUSION: Long-term survival with NED may be achievable by topotecan in selected patients with an initial diagnosis of extensive endometrial cancer despite repeated relapses and previous exposure to cisplatinum, an anthracycline and a taxane.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443400.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


73. Lanuke K, Mack LA, Temple WJ: A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Can J Surg; 2009 Feb;52(1):18-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We sought to investigate the incidence of perioperative venous thromboembolism (VTE)--pulmonary embolism, superior mesenteris vein thrombosis and deep vein thrombosis--in patients with peritoneal carcinomatosis after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.
  • All patients with VTE had extensive peritoneal disease and long durations of surgery: the median duration was 431 (range 330-683) minutes.
  • [MeSH-minor] Adenocarcinoma / therapy. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Incidence. Infusions, Parenteral. Male. Middle Aged. Prospective Studies. Pseudomyxoma Peritonei / therapy. Tachycardia / etiology. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):809-15 [10737280.001]
  • [Cites] Am J Transplant. 2007 Jan;7(1):185-94 [17227567.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):896-903 [11679989.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):787-95 [11776492.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):26-33 [12511145.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):508-13 [12794016.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):61-7 [14755505.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):387-92 [15070598.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):338S-400S [15383478.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):89-95 [16371741.001]
  • [Cites] Br J Surg. 2006 Jan;93(1):100-4 [16302177.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):186-90 [16303281.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1144-53 [16456817.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1112-8 [16505431.001]
  • [Cites] Thromb Haemost. 2006 Apr;95(4):752-4 [16601855.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):635-44 [16523363.001]
  • [Cites] Curr Opin Pulm Med. 2006 Sep;12(5):291-8 [16926640.001]
  • [Cites] Anesthesiology. 2006 Nov;105(5):1034-46 [17065899.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):911-6 [16626920.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):41-4 [10861608.001]
  • (PMID = 19234647.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2637643
  •  go-up   go-down


74. Gil-Moreno A, Maffuz A, Díaz-Feijoo B, Puig O, Martínez-Palones JM, Pérez A, García A, Xercavins J: Modified approach for extraperitoneal laparoscopic staging for locally advanced cervical cancer. J Exp Clin Cancer Res; 2007 Dec;26(4):451-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient was excluded due to peritoneal carcinomatosis.
  • The proposed modified surgical technique offers some advantages, is an easier approach because the parietal pelvic peritoneum is elastic and this helps to avoid its disruption at time of trocar insertion, size of incision is shorter, we achieved no CO2 leak through the trocar orifice, and wound suture is fast and simple.
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome


75. Bevanda M, Orsolic N, Basic I, Vukojevic K, Benkovic V, Horvat Knezevic A, Lisicic D, Dikic D, Kujundzic M: Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2. Int J Hyperthermia; 2009 Mar;25(2):132-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2.
  • PURPOSE: The purpose of this study was to investigate the effect of local chemoimmunotherapy and hyperthermal intraperitoneal chemotherapy (HIPEC) in a mouse model of induced peritoneal carcinomatosis.
  • MATERIAL AND METHODS: Peritoneal carcinomatosis in mice was produced by intraperitoneal implantation of MCa cells (5 x 10(3)).
  • Interleukin-2 (4.1 x 10(4) IU/mouse) was injected into the abdominal cavity of mice at day 7 and 3 before implantation of tumour cells.
  • RESULTS: Combined treatment with Interleukin-2 (IL-2) and cytostatics (5-FU, CIS or MIT) significantly affected the development of peritoneal carcinomatosis and increased the survival of mice (ILS% - 37 degrees C = 29.88, 199.32, and 108.52, ILS% - 43 degrees C = 62.69, 260.50, and 178.05, respectively).
  • CONCLUSION: We would like to stress that treatment with IL-2 prior to tumour diagnosis is not clinically practical, rather, the manuscript attempts to describe an experimental proof of principle.
  • Results suggest the synergistic effect of hyperthermia, chemotherapy and immunotherapy; IL-2 significantly increases antitumor activity of hyperthermic chemotherapy and survival rate of mice with peritoneal carcinomatosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced / methods. Interleukin-2 / therapeutic use. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Animals. Body Temperature. Combined Modality Therapy. Disease Models, Animal. Female. Humans. Immunotherapy / methods. Male. Mice. Mice, Inbred CBA. Neoplasm Transplantation. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337913.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


76. Minicozzi A, Borzellino G, Momo EN, Segattini C, Pitoni F, Steccanella F, De Manzoni G: [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up]. Ann Ital Chir; 2008 Jul-Aug;79(4):231-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
  • [Transliterated title] Trattamento della carcinosi peritoneale con chirurgia citoriduttiva e chemioipertermia intraperitoneale (IHPC): morbilità e mortalità postoperatorie e risultati a breve termine.
  • BACKGROUND: In order to treat the peritoneal carcinomatosis from abdominal neoplasms has been recently proposed complete peritonectomy associated with IntraPeritoneal Hyperthermic Chemotherapy (IHPC).
  • METHODS: Twenty-four patients with peritoneal carcinomatosis or positive cytology at peritoneal washing were treated in our Department from January 2005 to October 2007.
  • Primary tumor was ovarian carcinoma in ten patients: four cases presented peritoneal surface malignancies (PSM) after any time from hysteroadnexectomy related to primary tumor, six cases synchronous PSM.
  • Primary tumor was gastric cancer in seven patients: the peritoneal washing was positive in four cases and, during follow-up period after gastrectomy, other two cases presented PSM.
  • Primary tumor was pseudomixoma peritonei in four patients; cytoreductive surgery and IHPC was carried as first line therapy in only one patient.
  • IHPC was carried out through abdominopelvic cavity for 60 minutes using a closed abdomen technique.
  • RESULTS: The mean Peritoneal Cancer Index (PCI) was 14.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Peritoneum / surgery. Postoperative Complications. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093624.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


77. Cordin J, Lehmann K, Schneider PM: Clinical staging of adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:73-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upper endoscopy establishes the tumor diagnosis by multiple biopsies and defines the tumor type (Siewert I-III), based on tumor localization in relation to the endoscopic cardia.
  • Diagnostic laparascopy is suggested in advanced (CT3/4) Siewert type II-III tumors to exclude peritoneal carcinomatosis.
  • [MeSH-minor] Endosonography. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676872.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


78. Cotte E, Passot G, Gilly FN, Glehen O: Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol; 2010 Jan 15;2(1):31-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection of patients and staging of peritoneal surface malignancies.
  • Peritoneal carcinomatosis (PC) is a common evolution of cancer of the gastrointestinal tract, and has been traditionally regarded as a terminal disease with short median survival.
  • Indications for treatment of PC with cytoreduction and HIPEC are now validated for several diseases: peritoneal mesothelioma, pseudomyxoma peritonei, PC from the appendix, and colorectal cancer.
  • Indications are still under discussion for gastric and ovarian carcinomatosis.
  • The extent of peritoneal carcinomatosis is, however, difficult to evaluate preoperatively, and precise evaluation is most often performed during surgical exploration.
  • Cytoreductive surgery associated with HIPEC for the treatment of peritoneal carcinomatosis should be performed for young patients with limited and resectable carcinomatosis, in specialized institutions involved in the management of peritoneal surface malignancies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160814.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999158
  • [Keywords] NOTNLM ; Performance status / Peritoneal Cancer Index / Peritoneal carcinomatosis / Selection / Staging
  •  go-up   go-down


79. Graber I, Dumortier J, Poncet G, Queneau PE, Mathevet P, Scoazec JY: Hepar lobatum carcinomatosum revealing an occult metastatic lobular carcinoma of the breast. Ann Diagn Pathol; 2010 Dec;14(6):438-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transjugular liver biopsy performed at diagnosis showed an extensive fibrosis, containing scattered tumor cells, typical of metastatic lobular carcinoma of the breast.
  • Four months later, after discovery of a rectal adenocarcinoma, a laparoscopy was performed; peritoneal carcinomatosis was discovered.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / secondary. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary
  • [MeSH-minor] Biopsy. Budd-Chiari Syndrome / diagnosis. Budd-Chiari Syndrome / pathology. Diagnosis, Differential. Drug Therapy. Fatal Outcome. Female. Humans. Liver / blood supply. Liver / pathology. Liver Cirrhosis / diagnosis. Liver Cirrhosis / drug therapy. Liver Cirrhosis / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074693.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Keramidas M, Josserand V, Righini CA, Wenk C, Faure C, Coll JL: Intraoperative near-infrared image-guided surgery for peritoneal carcinomatosis in a preclinical experimental model. Br J Surg; 2010 May;97(5):737-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative near-infrared image-guided surgery for peritoneal carcinomatosis in a preclinical experimental model.
  • BACKGROUND: This study compared the quality of surgery performed under conventional light with near-infrared (NIR) image-guided surgery using a tumour-targeting probe and a portable clinical grade imaging device in a mouse model of peritoneal carcinomatosis.
  • METHODS: Peritoneal carcinomatosis was induced by injection of luciferase-positive tumour cells, leading to the formation of small nodules in the peritoneal cavity.
  • CONCLUSION: NIR image-guided surgery improved the quality of surgery for peritoneal carcinomatosis by doubling the number of nodules detected and significantly reducing the duration of surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Journal of Surgery Society Ltd.
  • (PMID = 20309948.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Luminescent Proteins
  •  go-up   go-down


81. Ascencio M, Estevez JP, Delemer M, Farine MO, Collinet P, Mordon S: Comparison of continuous and fractionated illumination during hexaminolaevulinate-photodynamic therapy. Photodiagnosis Photodyn Ther; 2008 Sep;5(3):210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal carcinomatosis was obtained 26 days post-tumour induction.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Light. Ovarian Neoplasms / drug therapy. Peritoneum / pathology. Photochemotherapy
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Neoplasm Staging. Rats

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356657.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid; G7H20TKI67 / 5-aminolevulinic acid hexyl ester
  •  go-up   go-down


82. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D, French Surgical Association: Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer; 2010 Dec 15;116(24):5608-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients.
  • BACKGROUND: Peritoneal carcinomatosis (PC) from nonovarian malignancies long has been regarded as a terminal disease.
  • The principal origins of PC were colorectal adenocarcinoma (N = 523), pseudomyxoma peritonei (N = 301), gastric adenocarcinoma (N = 159), peritoneal mesothelioma (N = 88), and appendiceal adenocarcinoma (N = 50).
  • The overall median survival was 34 months; and the median survival was 30 months for patients with colorectal PC, not reached for patients with pseudomyxoma peritonei, 9 months for patients with gastric PC, 41 months for patients with peritoneal mesothelioma, and 77 months for patients with PC from appendiceal adenocarcinoma.
  • Independent prognostic indicators in multivariate analysis were institution, origin of PC, completeness of cytoreductive surgery, extent of carcinomatosis, and lymph node involvement.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / secondary. Carcinoma / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20737573.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Investigator] Karine A; Olivier T; Catherine A; Patrick R; Philippe G; Gwenael F; Pierre M; Cecile B; Frederic M; Jacques TJ; Marc P; Rasmy L; Vincent T; Emily L; Sylvaine D; Kurt Vd
  •  go-up   go-down


83. Arvieux C, Laval G, Mestrallet JP, Stefani L, Villard ML, Cardin N: [Treatment of malignant intestinal obstruction. A prospective study over 80 cases]. Ann Chir; 2005 Sep;130(8):470-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of malignant intestinal obstruction. A prospective study over 80 cases].
  • [Transliterated title] Traitement de l'occlusion intestinale sur carcinose péritonéale. Etude prospective à propos de 80 cas.
  • AIM: Of the work: evaluation of a multidisciplinary strategy and a prospective medicosurgical protocol for the treatment of occlusion due to unresectable peritoneal carcinomatosis.
  • PATIENTS AND METHODS: All the included patients had occlusion and intraabdominal carcinomatosis.
  • [MeSH-major] Carcinoma / complications. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Palliative Care. Peritoneal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084483.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Analgesics; 0 / Antiemetics
  •  go-up   go-down


84. Capone A, Valle M, Proietti F, Federici O, Garofalo A, Petrosillo N: Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol; 2007 Nov 1;96(6):507-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis.
  • BACKGROUND: Peritoneal carcinomatosis is a common evolution of many abdominal and pelvic malignancies.
  • The increasing role of this surgery for the treatment of peritoneal carcinomatosis should strengthen the need for a careful evaluation of possible risk factors for postoperative infections, including the role of colonizing organisms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bacterial Infections / etiology. Carcinoma / drug therapy. Carcinoma / surgery. Chemotherapy, Adjuvant. Hyperthermia, Induced. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708508.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Stang A, Celebcioglu S, Keles H, von Seydewitz C, Malzfeldt E: [Minimally-invasive regional treatment of a symptomatic ischial metastasis using radiofrequency ablation and osteoplasty]. Dtsch Med Wochenschr; 2005 May 13;130(19):1195-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient refused further surgery, radiotherapy or chemotherapy, as she had been treated for ovarian cancer and recurring rectal carcinoma with peritoneal carcinomatosis for the last three years almost without interruption and experienced several complications.
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Female. Humans. Karnofsky Performance Status. Lung Neoplasms / secondary. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Palliative Care / methods. Peritoneal Neoplasms / secondary. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15875261.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Franiel T, Diederichs G, Engelken F, Elgeti T, Rost J, Rogalla P: Multi-detector CT in peritoneal carcinomatosis: diagnostic role of thin slices and multiplanar reconstructions. Abdom Imaging; 2009 Jan-Feb;34(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-detector CT in peritoneal carcinomatosis: diagnostic role of thin slices and multiplanar reconstructions.
  • BACKGROUND: In order to investigate whether 1-mm thin slices and multiplanar reconstructions (MPRs) of multi-detector computed tomography (CT) datasets interpreted in addition to isotropic 5-mm thick slices in one session improve the detection of peritoneal carcinomatosis.
  • METHODS: The abdominal CT datasets of 44 patients with histologically proven tumors of the abdomen or pelvis were retrospectively evaluated for peritoneal carcinomatosis by four radiologists with variable experience (radiologist 1: >or=10 years, radiologists 2 and 3: 1.5 years, radiologist 4: 0.5 years).
  • CONCLUSIONS: While 5-mm slices are sufficient for the detection of peritoneal carcinomatosis, 1-mm slices and MPRs can improve sensitivity and diagnostic confidence.
  • [MeSH-major] Carcinoma / radiography. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264738.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


87. Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, Trarbach T, Staib L, Kirchner T, Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P: [Specific treatment situations in metastatic colorectal cancer]. Onkologie; 2010;33 Suppl 4:8-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with unresectable liver metastases--with the associated difficulty of classification due to the lack of clear and definitive criteria--preoperative systemic therapy to induce 'conversion' is indicated, in order to allow secondary resection.
  • Lung metastases, too, or local peritoneal carcinomatosis can nowadays be operated on in selected patients with a good prospect of long-term remission or even cure.
  • The surgery should, however, generally only be carried out in experienced centers, especially in the case of peritoneal carcinomatosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Appendiceal Neoplasms / drug therapy. Appendiceal Neoplasms / mortality. Appendiceal Neoplasms / surgery. Chemotherapy, Adjuvant. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Humans. Neoadjuvant Therapy. Prognosis


88. Janot MS, Kersting S, Chromik AM, Tannapfel A, Uhl W: [Amyloidosis of the small intestine following whipple operation is a rare cause of chronic ileus and has to be considered as differential diagnosis]. Zentralbl Chir; 2010 Aug;135(4):345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Amyloidosis of the small intestine following whipple operation is a rare cause of chronic ileus and has to be considered as differential diagnosis].
  • INTRODUCTION: When patients who underwent a Whipple operation because of a tumour of the pancreas develop symptoms of chronic ileus several months after surgery, the most common cause is a relapse of tumour growth or a peritoneal carcinomatosis.
  • In this paper we report that secondary amyloidosis of the small intestine can produce similar symptoms and has to be evaluated as a rare differential diagnosis in chronic ileus.
  • CONCLUSION: Secondary amyloidosis following the Whipple operation is a rare reason for the symptoms of chronic ileus.
  • Surgeons have to keep in mind that amyloidosis is a possible differential diagnosis in addition to relapse of tumour growth and peritoneal carcinomatosis in these patients.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Amyloidosis / diagnosis. Cystadenoma, Mucinous / surgery. Ileus / diagnosis. Intestinal Diseases / diagnosis. Intestine, Small. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Postoperative Complications / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Chronic Disease. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Tissue Adhesions / diagnosis. Tissue Adhesions / pathology. Tissue Adhesions / surgery

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart ˙ New York.
  • (PMID = 20464655.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Sugarbaker PH: A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol; 2005 Dec;32(6 Suppl 9):S68-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A curative approach to peritoneal carcinomatosis from colorectal cancer.
  • One area of treatment failure for gastrointestinal cancer, the peritoneal surface, presents itself as a dominant need for improved understanding and for concentrated research activities.
  • Until recently, peritoneal carcinomatosis has been regarded as a universally fatal condition; however, recent success toward a curative approach is the result of two treatment innovations specifically developed for management of peritoneal carcinomatosis; these include surgical interventions (collectively referred to as peritonectomy), and the use of perioperative intraperitoneal chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Colorectal Neoplasms / pathology. Digestive System Surgical Procedures. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Humans. Infusions, Parenteral. Peritoneum / drug effects. Peritoneum / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399436.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


90. Capone G, Della Pepa GM, Sabatino G, Bartoccioni E, Albanese A, Mannino S, Maira G: A rare bone-leptomeningeal metastasis from an adrenal cortical carcinoma. J Clin Neurosci; 2009 Jul;16(7):977-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, the patient underwent excision of the mass; histopathological diagnosis confirmed that it was an ACC metastasis.
  • At post-operative follow-up, the patient was in a good neurological condition with no radiological evidence of a cranial recurrence; however, there was a voluminous abdominal regrowth of the primary tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Bone Neoplasms / secondary. Meningeal Carcinomatosis / secondary

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375918.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


91. Gómez Portilla A: [Peritoneal carcinomatosis of colorectal origin. An ethical problem today, a legal problem in the future]. Cir Esp; 2006 Jun;79(6):386-7; author reply 387
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal carcinomatosis of colorectal origin. An ethical problem today, a legal problem in the future].
  • [Transliterated title] Carcinomatosis peritoneal de origen colorrectal, problema ético hoy, un problema legal en el futuro.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cir Esp. 2005 Dec;78(6):344-50 [16420859.001]
  • (PMID = 16769007.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comment; Letter
  • [Publication-country] Spain
  •  go-up   go-down


92. Koppe MJ, Hendriks T, Boerman OC, Oyen WJ, Bleichrodt RP: Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med; 2006 Nov;47(11):1867-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis.
  • The aim of the present studies was to assess the efficacy of adjuvant radiommunotherapy using radiolabeled monoclonal antibodies after cytoreductive surgery in rats with peritoneal carcinomatosis of colonic origin.
  • METHODS: We used a tumor model, in which peritoneal carcinomatosis was induced by intraperitoneal inoculation of CC-531 colon carcinoma cells in Wag/Rij rats.
  • CONCLUSION: This study provides proof of principle that radiommunotherapy can be an effective treatment modality when applied as an adjuvant treatment after resection of tumors with a high risk of recurrence, such as after cytoreductive surgery of peritoneal carcinomatosis.
  • [MeSH-major] Colonic Neoplasms / surgery. Colonic Neoplasms / therapy. Neoplasms / radiotherapy. Peritoneal Neoplasms / surgery. Peritoneal Neoplasms / therapy. Radioimmunotherapy / methods. Radioimmunotherapy / trends

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2006 Nov;47(11):1746-8 [17079805.001]
  • (PMID = 17079821.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Iodine Radioisotopes
  •  go-up   go-down


93. Aguiar S Jr: Peritoneal carcinomatosis from colorectal cancer: the need for improving selection criteria for cytoreductive surgery and intraperitoneal chemotherapy. J Surg Oncol; 2010 Nov 1;102(6):563-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis from colorectal cancer: the need for improving selection criteria for cytoreductive surgery and intraperitoneal chemotherapy.
  • [MeSH-major] Carcinoma / secondary. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Surg Oncol. 2010 Nov 1;102(6):565-70 [20976729.001]
  • (PMID = 20976728.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


94. Sawamura A: [Surgical intervention in palliative care]. Nihon Rinsho; 2007 Jan;65(1):89-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In palliative care, surgical intervention is contra-indicated if there is intra-abdominal carcinomatosis as evidenced by diffuse intra-abdominal tumors, and massive ascites which re -accumulates rapidly after paracentesis.

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233421.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


95. Pfisterer J, Harter P, Hilpert F, du Bois A: [Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results]. Chirurg; 2007 Dec;78(12):1111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results].
  • [Transliterated title] Peritoneal metastasiertes Ovarialkarzinom. Vorgehensweise und Behandlungsergebnisse.
  • [MeSH-major] Ovarian Neoplasms / surgery. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Female. Humans. Infusions, Intravenous. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Reoperation. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):554-8 [16725183.001]
  • [Cites] Am J Obstet Gynecol. 2006 Aug;195(2):585-9; discussion 589-90 [16730631.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):489-97 [11520145.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1083-90 [16890277.001]
  • [Cites] Obstet Gynecol. 2006 Jan;107(1):77-85 [16394043.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):655-60 [15350355.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2489-97 [15590951.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):437-43 [17264340.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):27-32 [16368440.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):188-90 [7729732.001]
  • [Cites] J Am Coll Surg. 2006 Oct;203(4):527-32 [17000397.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] World J Surg Oncol. 2004 Jun 28;2:21 [15222884.001]
  • [Cites] Am J Obstet Gynecol. 2005 Aug;193(2):582-6; discussion 586-8 [16098902.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):843-6 [1550150.001]
  • (PMID = 17994201.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


96. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki I: Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res; 2006 Feb 15;66(4):2181-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
  • Peritoneal carcinomatosis is a frequent cause of death in patients with advanced gastric carcinoma.
  • Because chemokines are now considered to play an important role in the metastasis of various malignancies, we hypothesized that they may be involved in the development of peritoneal carcinomatosis by gastric carcinoma.
  • Human gastric carcinoma cell lines, which were all highly efficient in generating malignant ascites in nude mice upon i.p. inoculation, selectively expressed CXCR4 mRNA and protein.
  • Malignant ascitic fluids from patients with peritoneal carcinomatosis contained high concentrations of CXCL12 (4.67 ng/mL).
  • Moreover, immunohistochemical analysis showed that 22 of 33 primary gastric tumors with peritoneal metastasis were positive for CXCR4 expression (67%), whereas only 4 of 16 with other distant metastasis were positive (25%).
  • Notably, 22 of 26 CXCR4-expressing primary tumors developed peritoneal metastases (85%).
  • CXCR4 positivity of primary gastric carcinomas significantly correlated with the development of peritoneal carcinomatosis (P < 0.001).
  • Collectively, our results strongly suggest that the CXCR4/CXC12 axis plays an important role in the development of peritoneal carcinomatosis from gastric carcinoma.
  • Thus, CXCR4 may be a potential therapeutic target for peritoneal carcinomatosis of gastric carcinoma.
  • [MeSH-major] Carcinoma / secondary. Chemokines, CXC / physiology. Peritoneal Neoplasms / secondary. Receptors, CXCR4 / physiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Animals. Ascites / metabolism. Ascites / prevention & control. Cell Line, Tumor. Chemokine CXCL12. Female. Heterocyclic Compounds / pharmacology. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2006 Apr 1;66(7):3957
  • (PMID = 16489019.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Heterocyclic Compounds; 0 / Receptors, CXCR4; 155148-31-5 / JM 3100
  •  go-up   go-down


97. Verwaal VJ: Cytoreduction and HIPEC for peritoneal carcinomatosis from colorectal origin: the Amsterdam experience. Acta Chir Belg; 2006 May-Jun;106(3):283-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreduction and HIPEC for peritoneal carcinomatosis from colorectal origin: the Amsterdam experience.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced. Peritoneal Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909999.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


98. Yang XJ, Li Y, Yonemura Y: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol; 2010 May 1;101(6):457-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center.
  • METHODS: CRS and HIPEC were performed on 28 GC patients with peritoneal carcinomatosis (PC) and/or malignant ascites, with survival and perioperative safety as study endpoints.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / complications. Carcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Gastrectomy. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20401915.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol; 2010 Jan 1;28(1):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.
  • PURPOSE Peritoneal carcinomatosis (PC) from colorectal cancer traditionally is considered a terminal condition.
  • CONCLUSION This combined treatment approach against PC achieved low postoperative morbidity and mortality, and it provided good long-term survival in patients with peritoneal scores lower than 20.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / therapy. Peritoneal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2010 Apr 1;28(10):1808
  • (PMID = 19917863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. de Pangher Manzini V: Malignant peritoneal mesothelioma. Tumori; 2005 Jan-Feb;91(1):1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma.
  • BACKGROUND: The clinical characteristics of malignant peritoneal mesothelioma are not fully known, and it appears as a variable entity with different types of clinical presentation and with a difficult diagnosis.
  • PATIENTS: Fifteen patients with malignant peritoneal mesothelioma were analyzed for asbestos exposure, clinical presentation, thrombocytosis, X-rays and echotomographic findings, peritoneal fluid cytology, surgical investigations, diagnosis in vita, therapy, cause of death, diagnosis time, and survival time.
  • Abdominal pain, ascites, abdominal mass, weight loss and fever were the most common presentation symptoms.
  • Assembling the presenting symptoms, malignant peritoneal mesothelioma was subdivided in 3 types: classical (6 cases), surgical (5 cases) and medical (4 cases).
  • Peritoneal fluid cytology was positive for neoplastic mesothelial cells in 8 of 10 cases.
  • Diagnosis in vita was malignant peritoneal mesothelioma for 13 patients, peritoneal carcinomatosis for 1, with only 1 autopsy diagnosis.
  • Mean symptoms-to-diagnosis time was 122 days (4-410), and mean symptoms-to-survival time was 345 days (45-1510).
  • CONCLUSIONS: Malignant peritoneal mesothelioma is a very unusual disease characterized by a difficult diagnosis, a rapid evolution, a poor response to therapy, and a very high prevalence of thrombocytosis.
  • A new clinical classification into three types (classical, surgical and medical) may be useful for a correct diagnosis.
  • The early diagnosis of malignant peritoneal mesothelioma remains an important open question.
  • [MeSH-major] Mesothelioma. Peritoneal Neoplasms

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849996.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 1332-21-4 / Asbestos
  •  go-up   go-down






Advertisement